Microorganism producing purine nucleotides and method for producing purine nucleotides using same
Patent Information
- Application Number
- MYPI2025003375
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-08
- Filing Date
- 2023-12-07
- Publication Date
- 2024-06-08
AI Technical Summary
Current methods for producing purine nucleotides, such as 5'-inosine monophosphate (IMP), 5'-xanthosine monophosphate (XMP), and 5'-guanosine monophosphate (GMP), face challenges including raw material supply issues, economic feasibility, and low yield due to cell membrane permeability problems, especially during microbial fermentation where oxidative stress from reactive oxygen species (ROS) affects microorganism growth and productivity.
A microorganism with weakened serine dehydratase protein activity is used for culturing in a medium to enhance purine nucleotide production, where the serine dehydratase protein activity is adjusted, and proteins like formic acid dehydrogenase, glycine degrading enzyme, serine hydroxymethyltransferase, and formate-dependent phosphoribosylglycinamide formyl transferase activities are modified to improve yield.
This approach results in a high-yield production of purine nucleotides, effectively addressing the limitations of existing methods by enhancing the microorganism's ability to produce these nucleotides, even under stressful fermentation conditions.
Abstract
Description
Microorganism producing purine nucleotides and method for producing purine nucleotides using the same
[0001] The present application relates to a microorganism having a weakened serine dehydratase protein activity compared to its intrinsic activity; a method for producing a purine nucleotide, comprising a step of culturing the microorganism in a medium; a composition for producing a purine nucleotide, comprising the microorganism, a culture of the microorganism, a fermentation product of the microorganism, or a combination of two or more thereof; and a use of the microorganism for producing a purine nucleotide.
[0002]
[0003] Purine nucleotides, such as 5'-inosine monophosphate (IMP), 5'-xanthosine monophosphate (XMP), and 5'-guanosine monophosphate (GMP), are intermediates in the nucleic acid biosynthesis metabolic chain, play important physiological roles in the body, and are widely used in foods, medicines, etc. Specifically, IMP is known to have a beefy flavor on its own, and GMP, which is derived from XMP, is known to have a mushroomy flavor. Both substances are known to enhance the flavor of monosodium glutamate (MSG), and are thus attracting attention as a savory nucleic acid seasoning.
[0004] Meanwhile, methods for producing the above purine nucleotides include (1) a method of enzymatically decomposing ribonucleic acid (RNA) extracted from yeast cells, (2) a fermentation production method of culturing microorganisms that produce the same and directly recovering purine nucleotides in the culture medium, (3) a method of chemically phosphorylating nucleosides produced by fermentation, and (4) a method of enzymatically phosphorylating nucleosides produced by fermentation (Korean Patent Registration No. 10-1049023, Japanese Patent Registration No. 4363042, Korean Patent Registration No. 10-1210704, Agri. Biol. Chem., 36(9), 1511-1522). Among these, method (1) has problems with raw material supply and economic feasibility, and method (2) is widely used because it is advantageous in both economic and environmental aspects. Meanwhile, in the case of production of GMP, one of the purine nucleotides, there is a disadvantage of low yield due to the problem of cell membrane permeability, so a method of producing GMP by enzymatically converting XMP produced through microbial fermentation is also being utilized.
[0005] However, during the fermentative production of purine nucleotides using microorganisms, the microorganisms experience stress due to factors such as temperature, pH, osmotic pressure, nutrient deficiencies, and oxidative stress. Oxidative stress, in particular, is primarily caused by reactive oxygen species (ROS), an unavoidable element generated during fermentation, which can lead to abnormal microbial growth.
[0006] Therefore, research is still needed for effective purine nucleotide production.
[0007]
[0008] The present inventors have developed a method for producing purine nucleotides, including a step of culturing the microorganism in a medium, wherein the serine dehydratase protein activity is weakened compared to the intrinsic activity, a composition for producing purine nucleotides, including the microorganism, a culture of the microorganism, a fermentation product of the microorganism, or a combination of two or more thereof, and a use of the microorganism for producing purine nucleotides, thereby completing the present application.
[0009]
[0010] One aspect of the present application provides a microorganism having purine nucleotide production ability, wherein serine dehydratase protein activity is weakened compared to the intrinsic activity.
[0011] In one specific example, the serine dehydratase may be composed of an amino acid sequence of SEQ ID NO: 66.
[0012] A microorganism according to any one of the preceding specific examples, wherein the microorganism may further have one or more protein activities selected from the group consisting of (a) to (d) regulated:
[0013] (a) Formate dehydrogenase protein activity is weakened compared to intrinsic activity;
[0014] (b) Glycine catabolism enzyme protein protein activity is enhanced compared to the intrinsic activity;
[0015] (c) enhanced serine hydroxymethyltransferase protein activity compared to intrinsic activity; and
[0016] (d) Enhanced formate-dependent phosphoribosylglycinamide formyl transferase protein activity compared to intrinsic activity.
[0017] A microorganism according to any one of the preceding specific examples, wherein the microorganism may be a microorganism of the genus Corynebacterium.
[0018] As a microorganism according to any one of the preceding specific examples, the microorganism of the genus Corynebacterium may be Corynebacterium stationaris.
[0019] A microorganism according to any one of the preceding specific examples, wherein the microorganism may have an increased ability to produce purine nucleotides compared to a non-modified microorganism.
[0020] Another aspect of the present application provides a method for producing purine nucleotides, comprising the step of culturing a microorganism in a medium in which serine dehydratase protein activity is weakened compared to the intrinsic activity.
[0021] In one specific example, the method may additionally include a step of recovering a target substance from the cultured microorganism, a culture of the microorganism, a fermented product of the microorganism, or the culture medium.
[0022] Another aspect of the present application provides a composition for producing purine nucleotides, comprising a microorganism having a weakened serine dehydratase protein activity compared to its intrinsic activity, a culture of the microorganism, a fermentation product of the microorganism, or a combination of two or more thereof.
[0023] Another aspect of the present application provides a use of a microorganism having a weakened serine dehydratase protein activity compared to its intrinsic activity for producing purine nucleotides.
[0024]
[0025] The microorganism of the present invention, in which the serine dehydratase protein activity is weakened compared to the intrinsic activity, can produce purine nucleotides at a high yield, and thus can be usefully utilized in the industrial production of purine nucleotides.
[0026]
[0027] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below.
[0028] Furthermore, those skilled in the art will recognize or be able to ascertain, using only routine experimentation, numerous equivalents to the specific embodiments of the present application described herein. Furthermore, such equivalents are intended to be encompassed by this application.
[0029] As used in the specification and appended claims of this application, the singular articles "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Unless the context clearly dictates otherwise, the singular terms include the plural and the plural terms include the singular. In the specification and appended claims of this application, unless the context clearly dictates otherwise, the use of "or" is intended to include "and / or."
[0030]
[0031] In this application, the term "about" may be used before a specific numerical value. As used herein, the term "about" encompasses not only the exact number described after the term, but also a range that is or is nearly that number. Whether a number is or is nearly the specific number described can be determined based on the context in which it is presented. For example, the term "about" may refer to a range of -10% to +10% of a numerical value. In another example, the term "about" may refer to a range of -5% to +5% of a given numerical value. However, this is not a limitation.
[0032] In this application, the terms "first, second, third," "i), ii), iii)…" or "(a), (b), (c), (d)…" are used to distinguish similar configurations, and these terms do not imply that the steps are performed consecutively or in order. For example, when the terms are used in connection with steps of a method, use, or analysis, these steps may be performed simultaneously, without a time interval, or may be performed at intervals of seconds, minutes, hours, days, or months.
[0033] In this application, the term "consisting essentially of" means that a non-specific component may be present if the characteristics of the subject matter claimed in this application are not substantially affected by the presence of the non-specific component.
[0034] In this application, the term "consisting of" means that the proportion of a specific component(s) totals 100%. The components or features listed below the term "consisting of" may be essential or mandatory. In some embodiments, other than the components or features listed below "consisting of," other optional or nonessential components may be excluded.
[0035] In this application, the term "comprising" means the presence of a feature, step, or component described below, and does not exclude the presence or addition of one or more features, steps, or components. The components or features described below "comprising" in this application may be essential or mandatory, but in some embodiments, other optional or non-essential components or features may be further included.
[0036]
[0037] One aspect of the present application provides a microorganism having purine nucleotide production ability, wherein serine dehydratase protein activity is weakened compared to the intrinsic activity.
[0038] The above weakened serine dehydratase protein activity may be defined as an increased purine nucleotide production ability of the microorganism of the present application compared to the production ability of a natural wild-type microorganism or an unmodified microorganism (e.g., a microorganism expressing a polypeptide having wild-type serine dehydratase protein activity (e.g., a polypeptide of SEQ ID NO: 66) or a strain in which the serine dehydratase protein activity of the present application is not weakened compared to the intrinsic activity or before being weakened), but is not limited thereto.
[0039] For example, the serine dehydratase protein activity can be measured by measuring purine nucleotide production ability or yield, but is not limited thereto.
[0040]
[0041] In this application, the term "L-serine dehydratase" is an enzyme that catalyzes the chemical reaction of L-serine ↔ pyruvate + NH3. The serine dehydratase of the present application can be used interchangeably with SdaA or L-serine ammonia decomposition enzyme. Specifically, the serine dehydratase of the present application may be a protein having serine dehydratase activity encoded by the sdaA gene, but is not particularly limited in type as long as it has an activity corresponding to serine dehydratase. The serine dehydratase encoded by the sdaA gene is known in the art, and the amino acid and polynucleotide sequences of the serine dehydratase can be obtained from known databases, including, but not limited to, NCBI's GenBank.
[0042] For example, the serine dehydratase protein may include the amino acid sequence of SEQ ID NO: 66 or an amino acid sequence having at least 60% homology or identity thereto, but is not limited thereto, as long as it has serine dehydratase protein activity. Specifically, the polypeptide having the serine dehydratase protein activity may have, include, consist of, or consist essentially of the amino acid sequence of SEQ ID NO: 66 or an amino acid sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity thereto. For example, the serine dehydratase protein may refer to a protein endogenously present in a microorganism of the genus Corynebacterium or Corynebacterium stationensis, but is not limited thereto, and specifically, may refer to a serine dehydratase protein consisting of an amino acid sequence of SEQ ID NO: 66 endogenously present in a microorganism of the genus Corynebacterium or Corynebacterium stationensis, but is not limited thereto.
[0043] In the present application, with respect to the amino acid sequence, even if it is described as a polypeptide “comprising” the amino acid sequence set forth in a specific sequence number, a polypeptide “consisting of” the amino acid sequence set forth in a specific sequence number, or a polypeptide or protein “having” the amino acid sequence set forth in a specific sequence number, it is obvious that a protein having an amino acid sequence in which a portion of the sequence is deleted, modified, substituted, conservatively substituted, or added is also included within the scope of the present application, as long as it has the same or corresponding activity as the protein consisting of the amino acid sequence of the corresponding sequence number. For example, if it has the same or corresponding activity as the above-mentioned mutant protein, it does not exclude sequence additions that do not alter the function of the protein before or after the amino acid sequence, mutations that may occur naturally, silent mutations thereof, or conservative substitutions, and it is obvious that even if it has such sequence additions or mutations, it is also within the scope of the present application.
[0044] For example, the variant polypeptide of the present invention may have sequence additions, naturally occurring mutations, silent mutations, or conservative substitutions at the N-terminus, C-terminus, and / or within the amino acid sequence that do not alter the function of the polypeptide. For example, the polypeptide may be conjugated to a signal (or leader) sequence at the N-terminus of a protein that is involved in the transfer of the protein co-translationally or post-translationally. Furthermore, the polypeptide may be conjugated to other sequences or linkers so that the polypeptide can be identified, purified, or synthesized.
[0045] In this application, the term "conservative substitution" refers to the replacement of one amino acid with another amino acid having similar structural and / or chemical properties. Such amino acid substitutions may generally occur based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. For example, positively charged (basic) amino acids include arginine, lysine, and histidine; negatively charged (acidic) amino acids include glutamic acid and aspartic acid; and amino acids with nonpolar side chains (nonpolar amino acids) include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline; Amino acids with polar or hydrophilic side chains (polar amino acids) include serine, threonine, cysteine, tyrosine, asparagine, and glutamine. As another example, amino acids with charged side chains include arginine, lysine, histidine, glutamic acid, and aspartic acid, while amino acids with uncharged side chains (also called neutral amino acids) include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. As another example, phenylalanine, tryptophan, and tyrosine can be classified as aromatic amino acids. As another example, valine, leucine, and isoleucine can be classified as branched amino acids.As another example, the 20 amino acids can be classified into five groups based on size: glycine, alanine, and serine; cysteine, proline, threonine, aspartic acid, and asparagine; valine, histidine, glutamic acid, and glutamine; isoleucine, leucine, methionine, lysine, and arginine; and phenylalanine, tryptophan, and tyrosine. However, this is not necessarily limited to these groups. Typically, conservative substitutions may have little or no effect on the activity of the polypeptide.
[0046]
[0047] Additionally, the base sequence encoding the above serine dehydratase may be a base sequence encoding a protein exhibiting the activity of serine dehydratase.
[0048] For example, the serine dehydratase protein having the amino acid sequence of SEQ ID NO: 66 may be encoded by a polynucleotide having or including a sequence of SEQ ID NO: 67 or a base sequence having at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with the sequence of SEQ ID NO: 67, or consisting of or consisting essentially of the base sequence, but is not limited thereto. In addition, the base sequence of SEQ ID NO: 67 can be obtained from a known database, such as, but not limited to, NCBI's GenBank.
[0049] In the present application, the gene comprising the base sequence of SEQ ID NO: 67 may be used interchangeably with a polynucleotide comprising the base sequence of SEQ ID NO: 67, a gene or polynucleotide having the base sequence of SEQ ID NO: 67, or a gene or polynucleotide consisting of the base sequence of SEQ ID NO: 67.
[0050] The polynucleotide of the present application may be modified in various ways in the coding region without changing the amino acid sequence of the serine dehydratase of the present application, due to codon degeneracy or in consideration of the preferred codons of the organism to which the serine dehydratase of the present application is to be expressed. Therefore, it is self-evident that the polynucleotide of the present application may also be translated into a polypeptide consisting of the amino acid sequence of the serine dehydratase of the present application or a polypeptide having homology or identity therewith due to codon degeneracy. For example, the polynucleotide of the present application may be SEQ ID NO: 67 or a degenerated sequence thereof.
[0051] As another example, the polynucleotide of the present application may have or include a base sequence having at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with SEQ ID NO: 67, or may consist of or consist essentially of a base sequence having at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with SEQ ID NO: 67, but is not limited thereto.
[0052] In addition, the polynucleotide of the present application may include, without limitation, a probe that can be prepared from a known gene sequence, for example, a sequence that hybridizes under stringent conditions with a complementary sequence to all or part of the polynucleotide sequence of the present application, as long as it is a sequence encoding the serine dehydratase of the present application.
[0053] As used herein, the terms "homology" or "identity" refer to the degree of relationship between two given amino acid sequences or base sequences, which may be expressed as a percentage. The terms homology and identity are often used interchangeably.
[0054] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences are generally capable of hybridizing under moderate or high stringency conditions, typically along at least about 50%, 60%, 70%, 80%, or 90% of the entire sequence or its entire length. It should be appreciated that hybridization also encompasses polynucleotides containing common codons or codons that are considered codon degenerate.
[0055] Whether any two polynucleotide or polypeptide sequences are homologous, similar or identical can be determined using known computer algorithms such as the "FASTA" program using default parameters, for example as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO et al.](1988) SIAM J Applied Math 48: 1073). For example, homology, similarity, or identity can be determined using BLAST or ClustalW from the National Center for Biotechnology Information database.
[0056] Homology, similarity or identity of polynucleotides or polypeptides can be determined by comparing sequence information using, for example, the GAP computer program disclosed in Smith and Waterman, Adv. Appl. Math (1981) 2:482, or, for example, Needleman et al. (1970), J Mol Biol. 48:443. In brief, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). The default parameters for the GAP program are (1) unitary matrices (containing values of 1 for identity and 0 for non-identity), the PAM Matrix (see the disclosure by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation (1978)), Gribskov et al (1986) Nucl. Acids Res. 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) permutation matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); and (3) no penalty for terminal gaps.
[0057] Additionally, whether any two polynucleotide or polypeptide sequences have homology, similarity or identity can be determined by comparing the sequences by Southern hybridization experiments under defined stringent conditions, and the defined appropriate hybridization conditions are within the scope of the art and can be determined by methods well known to those skilled in the art (e.g., J. Sambrook et al., Molecular Cloning, A Laboratory Manual; F. M. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York), but are not limited thereto.
[0058] In this application, the term "stringent conditions" refers to conditions that allow specific hybridization between polynucleotides. Such conditions are specifically described in the literature (see Sambrook et al., supra, 9.50-9.51, 11.7-11.8). For example, conditions under which polynucleotides having high homology or identity hybridize with each other, polynucleotides having 60% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology or identity hybridize with each other, and polynucleotides having lower homology or identity do not hybridize with each other, or conditions under which washing conditions of typical southern hybridization are performed once, specifically twice or three times, at a salt concentration and temperature equivalent to 60°C, 1×SSC, 0.1% SDS, specifically 60°C, 0.1×SSC, 0.1% SDS, and more specifically 68°C, 0.1×SSC, 0.1% SDS.
[0059] The above hybridization requires that the two nucleotides have complementary sequences, although mismatches between bases are possible depending on the stringency of the hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenosine is complementary to thymine, and cytosine is complementary to guanine. Accordingly, the polynucleotide of the present application may also include isolated nucleic acid fragments that are complementary in their entirety, as well as those with substantially similar base sequences.
[0060] For example, a polynucleotide having homology or identity with the polynucleotide of the present application can be detected using hybridization conditions including a hybridization step at a Tm value of 55°C and using the conditions described above. In addition, the Tm value may be, but is not limited to, 60°C, 63°C, or 65°C, and can be appropriately adjusted by a person skilled in the art depending on the purpose.
[0061] The appropriate stringency for hybridizing the polynucleotides depends on the length and degree of complementarity of the polynucleotides, variables which are well known in the art (e.g., J. Sambrook et al., supra).
[0062]
[0063] In the present application, the term "purine nucleotide" may specifically be at least one nucleotide selected from the group consisting of 5'-inosine monophosphate (hereinafter referred to as IMP), 5'-xanthosine monophosphate (hereinafter referred to as XMP), and 5'-guanosine monophosphate (hereinafter referred to as GMP). The IMP is a compound in which adenine is deaminated and refers to a nucleotide composed of one molecule each of hypoxanthine, ribose, and phosphate. It can be biosynthesized from 5'-phosphoribosyl-1-pyrophosphate (PRPP), and specifically, it can be formed by replacing the pyrophosphate group bonded to carbon 1 of PRPP with a nitrogen atom, and forming an imidazole ring and a pyrimidine ring over nine steps. The XMP refers to a nucleotide dehydrogenated from IMP. It can be synthesized from IMP by 5'-inosine-5'-monophosphate dehydrogenase. The GMP refers to a nucleotide having a structure in which a phosphate group forms an ester bond to the ribose portion of a guanosine molecule. The GMP can be synthesized by adding an ammonia molecule to XMP by 5'-guanosine biosynthetic enzyme (GMP synthase). The method for producing GMP from XMP and / or the means used in the method can be selected from known techniques.
[0064]
[0065] In this application, the term "microorganism (or strain)" includes both wild-type microorganisms and microorganisms that have undergone genetic modification, either naturally or artificially. It may be a microorganism that has a specific mechanism weakened or increased due to causes such as the insertion of an external gene or the increased or inactivated activity of an endogenous gene, and may be a microorganism that includes genetic modification for the production of a desired polypeptide, protein, or product. In this application, "microorganism" and "strain" may be used interchangeably without limitation with the same meaning.
[0066] For example, the microorganism of the present application may be, but is not limited to, a microorganism (e.g., a recombinant strain) whose serine dehydratase protein activity is weakened compared to its intrinsic activity.
[0067] In the present application, the term "microorganism having purine nucleotide production ability" refers to a prokaryotic or eukaryotic microbial strain capable of producing purine nucleotides within the organism, and may include both a microorganism in which the purine nucleotide production ability has been conferred on a parent strain lacking purine nucleotide production ability, and a microorganism that inherently has purine nucleotide production ability. The purine nucleotide production ability may be conferred or enhanced by species improvement.
[0068] In this application, the term "unmodified microorganism" does not exclude a strain that contains a mutation that can occur naturally in a microorganism, and may refer to a wild-type strain or a natural strain itself, or a strain before its characteristics are changed by genetic mutation due to natural or artificial factors. The "unmodified microorganism" may be used interchangeably with "pre-modified strain," "pre-modified microorganism," "unmodified strain," "unmodified microorganism," "pre-mutated parent strain," "wild-type microorganism," "reference microorganism," or "reference microorganism." In this application, the unmodified microorganism may refer to a strain in which the serine dehydratase protein activity of the present application is not weakened compared to the intrinsic activity or before it is weakened, but is not limited thereto. In addition, the unmodified microorganism in this application may be a microorganism comprising an amino acid sequence consisting of SEQ ID NO: 66 or a polynucleotide consisting of SEQ ID NO: 67, but is not limited thereto.
[0069]
[0070] For the purposes of the present application, the microorganism of the present application may include any microorganism capable of producing a desired purine nucleotide by having a weakened serine dehydratase protein activity compared to the intrinsic activity. For example, the microorganism of the present application is characterized by having an increased purine nucleotide production ability by having a weakened serine dehydratase protein activity compared to the intrinsic activity, and may be a genetically modified microorganism or a recombinant microorganism, but is not limited thereto. Specifically, the recombinant strain with increased purine nucleotide production ability may be a microorganism with increased purine nucleotide production ability compared to a natural wild-type microorganism or an unmodified microorganism having an intrinsic serine dehydratase protein activity, but is not limited thereto.
[0071] For example, a microorganism having purine nucleotide production ability is a prokaryotic or eukaryotic microbial strain capable of producing purine nucleotides within the organism, and may include both a microorganism having an inherent purine nucleotide production ability or a microorganism in which the purine nucleotide production ability is conferred on a parent strain that does not have purine nucleotide production ability due to the weakened serine dehydratase protein activity of the present application. The purine nucleotide production ability may be conferred or enhanced by species improvement.
[0072]
[0073] The above “intrinsic activity” refers to the activity of a specific polypeptide originally possessed by the parent strain or unmodified microorganism before the change in trait when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with “activity before modification.”
[0074] In this application, the term "weakening" of polypeptide activity encompasses both weakening of activity or absence of activity compared to the intrinsic activity. The term "weakening" may be used interchangeably with terms such as deficiency, inactivation, deletion, disruption, down-regulation, decrease, attenuation, repression, and reduction.
[0075] For example, the above weakening may mean, but is not limited to, a state in which the protein is active but not completely inactivated by deletion, and the activity of the protein is weakened compared to an unmodified microorganism, a wild-type strain, or a parent strain.
[0076] For example, the weakening may be, but is not limited to, inactivation. The inactivation may mean that the protein is not expressed at all, or if expressed, its activity is absent or weakened compared to the parent strain or the unmodified strain comprising the amino acid sequence of SEQ ID NO: 66.
[0077] The above weakening may also include cases where the activity of the polypeptide itself is weakened or eliminated compared to the activity of the polypeptide originally possessed by the microorganism due to mutation of the polynucleotide encoding the polypeptide, etc., cases where the overall level of polypeptide activity within the cell is lower than that of the natural strain due to inhibition of expression of the gene encoding the polypeptide or inhibition of translation into the polypeptide, cases where the gene is not expressed at all, and cases where the polypeptide has no activity even if the gene is expressed.
[0078] A weakening of a polypeptide's activity relative to its intrinsic activity means that the activity of a specific polypeptide is lower than that originally possessed by the parent strain or unmodified microorganism prior to transformation. Whether the polypeptide's activity is weakened can be determined by examining the degree of activity, expression level, or the amount of product secreted from the polypeptide.
[0079] For example, the weakening may be, but is not limited to, that the activity of the serine dehydratase protein is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about 5%, or 0% of the activity of the serine dehydratase protein of the parent strain or unmodified microorganism before the transformation.
[0080] For example, the above inactivation may mean that the serine dehydratase protein is not expressed at all or, even if expressed, its activity is absent or weakened compared to that of a non-modified microorganism.
[0081] Attenuation of the activity of such polypeptides can be accomplished by any method known in the art, including but not limited to, and can be achieved by application of various methods well known in the art (e.g., Nakashima N et al., Bacterial cellular engineering by genome editing and gene silencing. Int J Mol Sci. 2014;15(2):2773-2793, Sambrook et al. Molecular Cloning 2012, etc.).
[0082] Specifically, the weakening of the polypeptide activity of the present application is
[0083] 1) Deletion of all or part of a gene encoding a polypeptide;
[0084] 2) Modification of the expression control region (or expression control sequence) so as to weaken the expression of the gene encoding the polypeptide;
[0085] 3) Modification of the amino acid sequence constituting the polypeptide (e.g., deletion / substitution / addition of one or more amino acids in the amino acid sequence) so as to eliminate or weaken the activity of the polypeptide;
[0086] 4) Modification of a polynucleotide sequence encoding the polypeptide such that the activity of the polypeptide is eliminated or weakened (e.g., deletion / substitution / addition of one or more nucleotides on the nucleotide sequence of the polypeptide gene such that the polypeptide is modified such that the activity of the polypeptide is eliminated or weakened);
[0087] 5) Modification of the initiation codon or 5'-UTR region base sequence of a gene encoding a polypeptide;
[0088] 6) Introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to a transcript of the gene encoding the polypeptide;
[0089] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence in front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure that prevents attachment of ribosomes;
[0090] 8) Addition of a promoter transcribed in the opposite direction to the 3' end of the open reading frame (ORF) of the polynucleotide sequence encoding the polypeptide (Reverse transcription engineering, RTE); or
[0091] 9) It may be a combination of two or more of the above 1) to 8), but is not particularly limited thereto.
[0092] for example,
[0093] The above 1) deletion of part or all of the gene encoding the polypeptide may be the removal of the entire polynucleotide encoding the endogenous target polypeptide in the chromosome, replacement with a polynucleotide having a partial nucleotide sequence deleted, or replacement with a marker gene.
[0094] Methods for deleting part or all of a polynucleotide include, but are not limited to, deleting the polynucleotide by homologous recombination using a vector for chromosomal insertion into a microorganism, inducing mutations using light such as ultraviolet rays or chemicals, and selecting a strain with a deletion of the target gene from the resulting mutants. The method for deleting part or all of the gene may include a method using DNA recombination technology. For example, a nucleotide sequence or vector containing a nucleotide sequence homologous to the target gene may be injected into the microorganism to cause homologous recombination, thereby causing deletion of part or all of the gene. The injected nucleotide sequence or vector may include, but is not limited to, a dominant selection marker.
[0095] In addition, the above 2) modification of the expression control sequence may be a mutation in the expression control region (or expression control sequence) by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, or replacement with a sequence having weaker activity. The expression control region includes, but is not limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation.
[0096] In addition, the modification of the amino acid sequence or polynucleotide sequence of the above 3) and 4) may be, but is not limited to, a mutation in the sequence of the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide, such as deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so as to weaken the activity of the polypeptide, or replacement with an amino acid sequence or polynucleotide sequence improved to have weaker activity, or an amino acid sequence or polynucleotide sequence improved to have no activity. For example, the expression of a gene may be inhibited or weakened by introducing a mutation in the polynucleotide sequence to form a stop codon, but is not limited thereto.
[0097] In addition, the above 5) modification of the base sequence of the initiation codon or 5'-UTR region of the gene encoding the polypeptide may be, for example, a substitution with another initiation codon having a lower polypeptide expression rate than the endogenous initiation codon, but is not limited thereto.
[0098] The introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to the transcript of the gene encoding the polypeptide 6) above can be described, for example, with reference to the literature [Weintraub, H. et al., Antisense-RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986].
[0099] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence in front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure that makes attachment of ribosomes impossible may make mRNA translation impossible or slow it down.
[0100] 8) Addition of a promoter transcribed in the opposite direction to the 3' end of the ORF (open reading frame) of the polynucleotide sequence encoding the polypeptide (Reverse transcription engineering, RTE) may weaken the activity by creating an antisense nucleotide complementary to the transcript of the gene encoding the polypeptide.
[0101]
[0102] In the microorganism of the present application, modification of part or all of the polynucleotide may be induced by, but is not limited to, (a) homologous recombination using a vector for chromosome insertion into the microorganism or genome editing using engineered nucleases (e.g., CRISPR-Cas9) and / or (b) treatment with light and / or chemicals such as ultraviolet rays and radiation. The method for modifying part or all of the gene may include a method using DNA recombination technology. For example, a nucleotide sequence or vector containing a nucleotide sequence homologous to a target gene may be injected into the microorganism to cause homologous recombination, thereby causing deletion of part or all of the gene. The injected nucleotide sequence or vector may include, but is not limited to, a dominant selection marker.
[0103]
[0104] For example, the recombinant microorganism having purine nucleotide production ability of the present application may include any microorganism that is transformed through a vector and has the activity of the serine dehydratase protein of the present application weakened so as to produce purine nucleotides.
[0105] The vector of the present application may comprise a DNA construct comprising a base sequence of a polynucleotide encoding a target polypeptide operably linked to a suitable expression control region (or expression control sequence) so as to enable expression of the target polypeptide in a suitable host. The expression control region may comprise a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and sequences regulating the termination of transcription and translation. The vector may be capable of replicating or functioning independently of the host genome after being transformed into a suitable host cell, or may be integrated into the genome itself.
[0106] The vector used in the present application is not particularly limited, and any vector known in the art can be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A can be used as phage vectors or cosmid vectors, and pDZ series, pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, pSK series, pSKH series, and pET series can be used as plasmid vectors. Specifically, pDZ, pDC, pDCM2, pACYC177, pACYC184, pCL, pSK, pSKH130, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors, etc. can be used.
[0107] For example, a polynucleotide encoding a target polypeptide can be inserted into a chromosome via a vector for intracellular chromosomal insertion. The insertion of the polynucleotide into the chromosome can be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto. A selection marker for confirming the chromosomal insertion can be additionally included. The selection marker is used to select cells transformed with the vector, i.e., to confirm the insertion of the target nucleic acid molecule. Markers that confer a selectable phenotype, such as drug resistance, nutrient requirement, cytotoxic agent resistance, or expression of a surface polypeptide, can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or exhibit other phenotypic traits, so that transformed cells can be selected.
[0108] The term "transformation" in this application refers to introducing a vector containing a polynucleotide encoding a target polypeptide into a host cell or microorganism so that the polypeptide encoded by the polynucleotide can be expressed in the host cell. The transformed polynucleotide may be located within the chromosome of the host cell or located extrachromosomally, as long as it can be expressed in the host cell. In addition, the polynucleotide includes DNA and / or RNA encoding the target polypeptide. The polynucleotide may be introduced in any form as long as it can be introduced into the host cell and expressed. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a genetic construct containing all elements necessary for autonomous expression. The expression cassette may typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal, all of which are operably linked to the polynucleotide. The above expression cassette may be in the form of a self-replicating expression vector. Furthermore, the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not limited thereto.
[0109] As used herein, the term "operably linked" refers to a configuration in which a regulatory sequence is positioned appropriately to direct the expression of a coding sequence. Therefore, "operably linked" includes a regulatory region of a functional domain with known or desired activity, such as a promoter, terminator, signal sequence, or enhancer region, attached or linked to a target (gene or polypeptide) so as to regulate the expression, secretion, or function of the target in accordance with said known or desired activity. For example, it refers to a polynucleotide sequence that is operatively linked to a promoter sequence that initiates and mediates transcription of the polynucleotide encoding the target variant polypeptide of the present application.
[0110] As used herein, the term “expression” includes, but is not limited to, any step involved in the production of a polypeptide, such as transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
[0111] As used herein, the term "expression vector" means a linear or circular nucleic acid molecule comprising a coding sequence and regulatory sequences operably linked thereto for expression thereof.
[0112] As used herein, the term "regulatory sequence" refers to a polynucleotide sequence necessary for the expression of a coding sequence. Each regulatory sequence may be native to the coding sequence (having the same origin) or foreign (derived from another gene). Examples of the regulatory sequence include a leader sequence, a polyadenylation sequence, a propeptide sequence, a promoter, a signal peptide sequence, an operator sequence, a sequence encoding a ribosome binding site, and sequences that regulate transcription and translation termination. The minimum unit of the regulatory sequence may include a promoter, a transcription and translation termination sequence.
[0113] In relation to a cell, polynucleotide, polypeptide, or vector, the term "recombinant" in this application means that the cell, polynucleotide, polypeptide, or vector has been modified by the introduction of a heterologous nucleic acid or polypeptide or by alteration of a native polynucleotide or polypeptide, or that the cell is derived from a cell so modified. Thus, for example, a recombinant cell may express a gene not found in the native (non-recombinant) form of the cell, or may express a native gene that is expressed or not expressed at all, or otherwise abnormally expressed.
[0114]
[0115] For example, the microorganism producing the purine nucleotide may be a microorganism that endogenously comprises a protein consisting of an amino acid sequence of SEQ ID NO: 66, or a protein consisting of an amino acid sequence having at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, or 99.9% homology or identity with SEQ ID NO: 66.
[0116] For example, the microorganism producing the purine nucleotide may be a microorganism that inherently includes a polynucleotide sequence capable of encoding a protein including an amino acid sequence having at least 80% homology with the sequence of SEQ ID NO: 66, a base sequence of SEQ ID NO: 67, or a base sequence having at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with the base sequence of SEQ ID NO: 67.
[0117]
[0118] The microorganism of the present application may include all microorganisms in which the serine dehydratase protein activity is weakened compared to the intrinsic activity by various known methods.
[0119] As a specific example, the microorganism having a weakened serine dehydratase protein activity compared to the intrinsic activity of the present application may be, but is not limited to, a microorganism having a polynucleotide encoding the serine dehydratase protein that is missing or modified. Specifically, the microorganism may be, but is not limited to, a microorganism having a missing base sequence of SEQ ID NO: 67 and thus having no serine dehydratase protein activity.
[0120]
[0121] For example, the microorganism with increased purine nucleotide production ability of the present application may be a microorganism with increased purine nucleotide production ability compared to a non-modified microorganism, but is not limited thereto. For example, the non-modified microorganism, which is a target strain for comparing whether the purine nucleotide production ability is increased, may be the CJX1664 strain or the KCCM12151P strain, but is not limited thereto.
[0122] For example, the microorganism with increased purine nucleotide productivity may have an increase of about 1% or more, specifically, about 1% or more, about 2.5% or more, about 5% or more, about 6% or more, about 7% or more, about 8% or more, about 9% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, or about 35% or more (the upper limit is not particularly limited, and may be, for example, about 200% or less, about 150% or less, about 100% or less, about 50% or less, about 45% or less, or about 40% or less) compared to the purine nucleotide productivity of the parent strain or the non-modified microorganism before mutation, but is not limited thereto as long as it has a positive value increase compared to the productivity of the parent strain or the non-modified microorganism before mutation. In another example, the recombinant strain with increased purine nucleotide production ability may have an increased purine nucleotide production ability of about 1.1 times or more, about 1.15 times or more, about 1.2 times or more, about 1.25 times or more, about 1.3 times or more, or about 1.35 times or more (the upper limit is not particularly limited, and may be, for example, about 10 times or less, about 5 times or less, about 3 times or less, about 2 times or less, about 1.5 times or less, or about 1.4 times or less) compared to the parent strain before mutation or the unmodified microorganism, but is not limited thereto.
[0123]
[0124] For example, the microorganism having the ability to produce purine nucleotides may be either a prokaryotic cell or a eukaryotic cell, but may specifically be a prokaryotic cell. The prokaryotic cell may include, for example, a microbial strain belonging to the genus Escherichia sp., Erwinia sp., Serratia sp., Providencia sp., Corynebacteria sp., Pseudomonas sp., Leptospira sp., Salmonella sp., Brevibacteria sp., Hypomononas sp., Chromobacterium sp., and Norcardia sp., or a fungus or yeast. Specifically, it is a strain of a microorganism belonging to the genus Escherichia, the genus Corynebacterium, and the genus Leptospira, as well as yeast. More specifically, it may be a strain of a microorganism belonging to the genus Corynebacterium.
[0125] As a microorganism according to any one of the preceding specific examples, the microorganism of the present application may be a microorganism of the genus Corynebacterium.
[0126] As an example of the present application, the microorganism of the present application is Corynebacterium stationis, Corynebacterium glutamicum, Corynebacterium crudilactis, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium callunae, Corynebacterium singulare, Corynebacterium halotolerans, Corynebacterium striatum, Corynebacterium ammoniagenes, Corynebacterium It may be Corynebacterium pollutisoli, Corynebacterium imitans, Corynebacterium testudinoris, or Corynebacterium flavescens. Specifically, the microorganism of the present application may be a microorganism of the genus Corynebacterium, more specifically, Corynebacterium stationis or Corynebacterium glutamicum, but is not limited thereto.
[0127]
[0128] The microorganism having purine nucleotide production ability of the present application may be a microorganism having improved purine nucleotide production ability by further regulating the activity of at least one protein selected from the group consisting of (a) to (d), but is not limited thereto:
[0129] (a) Formate dehydrogenase protein activity is weakened compared to intrinsic activity;
[0130] (b) Glycine catabolism enzyme protein protein activity is enhanced compared to the intrinsic activity;
[0131] (c) enhanced serine hydroxymethyltransferase protein activity compared to intrinsic activity; and
[0132] (d) Enhanced formate-dependent phosphoribosylglycinamide formyl transferase protein activity compared to intrinsic activity.
[0133]
[0134] As used herein, the term "increase" of polypeptide activity means that the activity of the polypeptide is enhanced compared to its intrinsic activity. The term "increase" may be used interchangeably with terms such as activation, up-regulation, overexpression, and enhancement.
[0135] The above enhancement may include exhibiting an activity that was not originally present, or exhibiting an activity that is enhanced compared to the intrinsic activity or activity before modification.
[0136] For example, the above "exhibiting an activity that was not originally present" may be, but is not limited to, "introduction of a protein." The introduction of a protein means that a gene that the microorganism did not originally possess is expressed within the microorganism, thereby exhibiting the activity of a specific protein, or that the activity is enhanced or improved compared to the intrinsic activity or activity before modification of the protein. For example, a polynucleotide encoding a specific protein may be introduced into the chromosome of the microorganism, or a vector containing a polynucleotide encoding a specific protein may be introduced into the microorganism, thereby exhibiting its activity.
[0137] The above “intrinsic activity” refers to the activity of a specific polypeptide originally possessed by the parent strain or unmodified microorganism before the change in trait when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with “activity before modification.”
[0138] Enhancement of the activity of a polypeptide compared to its intrinsic activity means that the activity and / or concentration (expression amount) of a specific polypeptide is enhanced compared to the activity and / or concentration (expression amount) that the parent strain or unmodified microorganism originally had before the transformation.
[0139] For example, the enhancement may be, but is not limited to, an enhancement of the activity or concentration of the corresponding protein, typically by about 1%, about 10%, about 25%, about 50%, about 75%, about 100%, about 150%, about 200%, about 300%, about 400%, or about 500%, up to about 1000% or about 2000% or more, relative to the activity or concentration of the wild-type protein or the initial microbial strain.
[0140] Enhancement of the activity of the above polypeptide can be achieved by introducing an exogenous polypeptide or enhancing the activity of the endogenous polypeptide. Whether the activity of the above polypeptide is enhanced can be confirmed by enhancing the activity level of the polypeptide, the expression level, or the amount of the product excreted from the polypeptide.
[0141] Enhancement of the activity of the above polypeptide can be achieved by applying various methods well known in the art, and is not limited as long as the activity of the target polypeptide can be enhanced compared to that of the microorganism before modification. Specifically, it may be achieved by using genetic engineering and / or protein engineering, which are routine methods of molecular biology and are well known to those skilled in the art, but is not limited thereto (e.g., Sitnicka et al. Functional Analysis of Genes. Advances in Cell Biology. 2010, Vol. 2. 1-16, Sambrook et al. Molecular Cloning 2012, etc.).
[0142] Specifically, the enhancement of the activity of the polypeptide of the present application is
[0143] 1) Enhancing the intracellular copy number of a polynucleotide encoding a polypeptide;
[0144] 2) Modification of the gene expression control region on the chromosome encoding the polypeptide (e.g., mutation in the expression control region, replacement with a sequence having stronger activity, or insertion of a sequence having stronger activity);
[0145] 3) Modification of the base sequence encoding the initiation codon or 5'-UTR region of a gene transcript encoding a polypeptide;
[0146] 4) Modification of the amino acid sequence of the polypeptide so as to enhance polypeptide activity;
[0147] 5) Modification of the polynucleotide sequence encoding the polypeptide so as to enhance the activity of the polypeptide (e.g., modification of the polynucleotide sequence of the polypeptide gene so as to encode a polypeptide modified so as to enhance the activity of the polypeptide);
[0148] 6) Introduction of a foreign polypeptide exhibiting the activity of the polypeptide or a foreign polynucleotide encoding the same;
[0149] 7) Codon optimization of a polynucleotide encoding a polypeptide;
[0150] 8) Analyzing the tertiary structure of the polypeptide and selecting the exposed portion to modify or chemically modify; or
[0151] 9) It may be a combination of two or more of the above 1) to 8), but is not particularly limited thereto.
[0152] for example,
[0153] The above 1) intracellular copy number enhancement of a polynucleotide encoding a polypeptide may be achieved by introducing a vector capable of replicating and functioning independently of a host, to which the polynucleotide encoding the polypeptide is operably linked, into the host cell. Alternatively, the polynucleotide encoding the polypeptide may be introduced into a chromosome within the host cell in one copy or two or more copies. The introduction into the chromosome may be performed by introducing a vector capable of inserting the polynucleotide into the chromosome within the host cell, but is not limited thereto. The vector is as described above.
[0154] 2) Replacing the gene expression control region (or expression control sequence) on the chromosome encoding the polypeptide with a sequence having strong activity may be, for example, a mutation in the sequence such as deletion, insertion, non-conservative or conservative substitution, or a combination thereof to further enhance the activity of the expression control region, or replacement with a sequence having stronger activity. The expression control region may include, but is not particularly limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation. As an example, it may be, but is not limited to, replacing the original promoter with a strong promoter.
[0155] Examples of known strong promoters include, but are not limited to, the cj1 to cj7 promoters (US Patent No. US 7662943 B2), the lac promoter, the trp promoter, the trc promoter, the tac promoter, the lambda phage PR promoter, the PL promoter, the tet promoter, the gapA promoter, the SPL7 promoter, the SPL13 (sm3) promoter (US Patent No. US 10584338 B2), the O2 promoter (US Patent No. US 10273491 B2), the tkt promoter, and the yccA promoter.
[0156] 3) The above modification of the base sequence of the initiation codon or 5'-UTR region of the gene encoding the polypeptide may be, for example, a substitution of another initiation codon having a higher polypeptide expression rate than the endogenous initiation codon, but is not limited thereto.
[0157] The modification of the amino acid sequence or polynucleotide sequence of the above 4) and 5) may be, but is not limited to, a mutation in the sequence by deletion, insertion, non-conservative or conservative substitution or a combination thereof in the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide to enhance the activity of the polypeptide, or replacement with an amino acid sequence or polynucleotide sequence improved to have stronger activity or an amino acid sequence or polynucleotide sequence improved to have enhanced activity. The replacement may be specifically performed by inserting the polynucleotide into a chromosome by homologous recombination, but is not limited thereto. The vector used at this time may additionally include a selection marker to confirm whether or not the chromosome has been inserted. The selection marker is as described above.
[0158] The introduction of the foreign polynucleotide exhibiting the activity of the polypeptide as described above 6) may be the introduction into the host cell of a foreign polynucleotide encoding a polypeptide exhibiting the same / similar activity as the polypeptide. The foreign polynucleotide is not limited in its origin or sequence as long as it exhibits the same / similar activity as the polypeptide. The method used for the introduction may be performed by a person skilled in the art appropriately selecting a known transformation method, and the polypeptide may be produced by expressing the introduced polynucleotide in the host cell, thereby enhancing its activity.
[0159] The above 7) codon optimization of a polynucleotide encoding a polypeptide may be codon optimization of an endogenous polynucleotide to enhance transcription or translation within a host cell, or codon optimization of a foreign polynucleotide to optimize transcription or translation within a host cell.
[0160] The above 8) analyzing the tertiary structure of a polypeptide and selecting an exposed portion to modify or chemically modify may be done by, for example, comparing the sequence information of the polypeptide to be analyzed with a database storing the sequence information of known proteins, determining a template protein candidate based on the degree of sequence similarity, confirming the structure based on this, and selecting an exposed portion to modify or chemically modify, and modifying or modifying it.
[0161] Such enhancement of polypeptide activity may be, but is not limited to, enhancement of the activity or concentration of the corresponding polypeptide relative to the activity or concentration of the polypeptide expressed in the wild type or pre-transformed microbial strain, or an increase in the amount of a product produced from the polypeptide.
[0162]
[0163] As an example of the present application, the microorganism having purine nucleotide production ability of the present application may be a microorganism having an enhanced purine nucleotide production ability by further weakening the formate dehydrogenase protein activity compared to the intrinsic activity, but is not limited thereto.
[0164]
[0165] In this application, the term “formate dehydrogenase” is composed of formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2) and formate dehydrogenase subunit 3 (Fdh subunit 3), and catalyzes an oxidation reaction using formate as a substrate to produce NAD + It is an enzyme that reduces formate and produces NADH and CO2. Specifically, the formate dehydrogenase of the present application may be any one or more proteins selected from the group consisting of formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2), and formate dehydrogenase subunit 3 (Fdh subunit 3), but is not limited thereto. The formate dehydrogenase of the present application may be used to mean a complex of formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2), and formate dehydrogenase subunit 3 (Fdh subunit 3), and may be used interchangeably as Fdh.
[0166] The "fdh gene" of the present application may be used to mean a gene encoding formate dehydrogenase of the present application, which is composed of the fdh 1, fdh 2, and fdh 3 genes. Specifically, the fdh gene of the present application may be used to mean a gene encoding formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2), and formate dehydrogenase subunit 3 (Fdh subunit 3) complex of the present application.
[0167] Specifically, the formate dehydrogenase of the present application may be a protein having formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2), and formate dehydrogenase subunit 3 (Fdh subunit 3) activity encoded by the fdh 1, fdh 2, and fdh 3 genes, respectively, but is not particularly limited in type as long as it has an activity corresponding to formate dehydrogenase. Formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2), and formate dehydrogenase subunit 3 (Fdh subunit 3) encoded by the fdh 1, fdh 2, and fdh 3 genes, respectively, are known in the art, and the amino acid and polynucleotide sequences of each of the formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2), and formate dehydrogenase subunit 3 (Fdh subunit 3) can be obtained from known databases, including, but not limited to, NCBI's GenBank.
[0168] For example, the formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2), and formate dehydrogenase subunit 3 (Fdh subunit 3) may each include an amino acid sequence of SEQ ID NO: 68, SEQ ID NO: 70, and SEQ ID NO: 72, or an amino acid sequence having at least 60% homology or identity therewith, but is not limited thereto, as long as it has formate dehydrogenase protein activity. Specifically, the polypeptides having the formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2) and formate dehydrogenase subunit 3 (Fdh subunit 3) activities may have, include, consist of, or consist essentially of an amino acid sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 68, SEQ ID NO: 70, and SEQ ID NO: 72, respectively.For example, the formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2), and formate dehydrogenase subunit 3 (Fdh subunit 3) proteins may refer to proteins endogenously present in a microorganism of the genus Corynebacterium or Corynebacterium stationensis, but are not limited thereto, and specifically, may refer to a formate dehydrogenase subunit 1 (Fdh subunit 1) protein consisting of an amino acid sequence of SEQ ID NO: 68, a formate dehydrogenase subunit 2 (Fdh subunit 2) protein consisting of an amino acid sequence of SEQ ID NO: 70, and a formate dehydrogenase subunit 3 (Fdh subunit 3) protein consisting of an amino acid sequence of SEQ ID NO: 72, but are not limited thereto.
[0169] Additionally, the base sequence encoding the formate dehydrogenase may be a base sequence encoding a protein exhibiting the activity of formate dehydrogenase.
[0170] For example, the base sequence encoding the formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2), and formate dehydrogenase subunit 3 (Fdh subunit 3) may be a base sequence encoding a protein exhibiting formate dehydrogenase activity.
[0171] The formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2) and formate dehydrogenase subunit 3 (Fdh subunit 3) having amino acid sequences of SEQ ID NO: 68, SEQ ID NO: 70 and SEQ ID NO: 72, respectively, may be encoded by a polynucleotide having or including a base sequence having at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% and less than 100% homology or identity with the sequences of SEQ ID NO: 69, SEQ ID NO: 71 and SEQ ID NO: 73, respectively, or consisting of or consisting essentially of the base sequences, but are not limited thereto. In addition, the base sequences of SEQ ID NO: 69, SEQ ID NO: 71, and SEQ ID NO: 73, respectively, can be obtained from known databases, including, but not limited to, NCBI's GenBank.
[0172]
[0173] As an example of the present application, the microorganism having purine nucleotide production ability of the present application may be a microorganism having enhanced purine nucleotide production ability by further enhancing glycine decomposition enzyme protein activity compared to the intrinsic activity, but is not limited thereto.
[0174] In the present application, the term “glycine degradation enzyme protein” refers to a protein that is directly or indirectly involved in the glycine degradation pathway, and may be used to mean each protein constituting the glycine degradation system, a complex of the proteins, or the glycine degradation system itself. Specifically, the glycine degradation enzyme protein may be any one or more proteins selected from the group consisting of T-protein (GcvT), P-protein (GcvP), L-protein (GcvL), H-protein (GcvH) constituting the glycine degradation system, and LipB and LipA, which are coenzymes of the glycine degradation system, but is not limited thereto (John E. Cronan, Microbiology and Molecular Biology Reviews., 13 April 2016). The glycine degradation enzyme protein of the present application may be used interchangeably with GcvPTH or the glycine cleavage system.
[0175] In this application, the term “glycine cleavage system (GCV)” is composed of two or more subunits, namely subunits GcvP, GcvT and GcvH, which catalyze the cleavage of glycine by carbon dioxide, ammonium ion and N 5-10 - A multi-enzyme complex that catalyzes the oxidative decarboxylation and deamination of methylenetetrahydrofolate. The glycine cleavage system of the present invention can be used interchangeably with a glycine degradation system.
[0176] Specifically, the glycine hydrolase protein of the present application may be a protein having GcvP, GcvT and GcvH protein activity encoded by the gcvP, gcvT and gcvH genes, respectively, but is not particularly limited in type as long as it has an activity corresponding to the glycine hydrolase protein. The GcvP, GcvT and GcvH proteins encoded by the gcvP, gcvT and gcvH genes, respectively, are each known in the art, and the amino acid and polynucleotide sequences of the GcvP, GcvT and GcvH proteins, respectively, can be obtained from known databases, such as, but not limited to, NCBI's GenBank.
[0177] For example, the GcvP, GcvT and GcvH proteins may each comprise an amino acid sequence of SEQ ID NO: 74, SEQ ID NO: 76 and SEQ ID NO: 78 or an amino acid sequence having at least 60% homology or identity therewith, but are not limited thereto, as long as they have glycine catabolic enzyme protein activity. Specifically, the polypeptides having the GcvP, GcvT and GcvH protein activities may each have, comprise, consist of or consist essentially of an amino acid sequence of SEQ ID NO: 74, SEQ ID NO: 76 and SEQ ID NO: 78 or an amino acid sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity therewith. For example, the GcvP, GcvT, and GcvH proteins may refer to proteins endogenously present in a microorganism of the genus Corynebacterium or Corynebacterium stationensis, but are not limited thereto, and specifically, may refer to a GcvP protein consisting of an amino acid sequence of SEQ ID NO: 74, a GcvT protein consisting of an amino acid sequence of SEQ ID NO: 76, and a GcvH protein consisting of an amino acid sequence of SEQ ID NO: 78, but are not limited thereto.
[0178] Additionally, the base sequence encoding the GcvP, GcvT and GcvH proteins may be a base sequence encoding a protein exhibiting the activity of a glycine degrading enzyme protein.
[0179] For example, the GcvP, GcvT and GcvH proteins having the amino acid sequences of SEQ ID NO: 74, SEQ ID NO: 76 and SEQ ID NO: 78, respectively, may be encoded by a polynucleotide having or comprising a base sequence having at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% and less than 100% homology or identity with the sequences of SEQ ID NO: 75, SEQ ID NO: 77 and SEQ ID NO: 79, respectively, or consisting of or consisting essentially of the base sequence, but are not limited thereto. In addition, the base sequences of SEQ ID NO: 75, SEQ ID NO: 77, and SEQ ID NO: 79, respectively, can be obtained from known databases, including, but not limited to, NCBI's GenBank.
[0180]
[0181] As an example of the present application, the microorganism having purine nucleotide production ability of the present application may be a microorganism having enhanced purine nucleotide production ability by further enhancing serine hydroxymethyltransferase protein activity compared to the intrinsic activity, but is not limited thereto.
[0182] In this application, the term “serine hydroxymethyltransferase” is an enzyme that catalyzes the conversion of serine to glycine. The serine hydroxymethyltransferase of the present application may be used interchangeably with GlyA. Specifically, the serine hydroxymethyltransferase of the present application may be a protein having serine hydroxymethyltransferase activity encoded by the glyA gene, but is not particularly limited in type as long as it has an activity corresponding to serine hydroxymethyltransferase. The serine hydroxymethyltransferase encoded by the glyA gene is known in the art, and the amino acid and polynucleotide sequences of the serine hydroxymethyltransferase can be obtained from known databases, such as, but not limited to, NCBI’s GenBank.
[0183] For example, the serine hydroxymethyltransferase protein may include the amino acid sequence of SEQ ID NO: 80 or an amino acid sequence having at least 60% homology or identity therewith, but is not limited thereto, as long as it has serine hydroxymethyltransferase protein activity. Specifically, the polypeptide having the serine hydroxymethyltransferase protein activity may have, include, consist of, or consist essentially of the amino acid sequence of SEQ ID NO: 80 or an amino acid sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity therewith. For example, the serine hydroxymethyltransferase protein may refer to a protein endogenously present in a microorganism of the genus Corynebacterium or Corynebacterium stationensis, but is not limited thereto, and specifically, may refer to a serine hydroxymethyltransferase protein consisting of an amino acid sequence of sequence number 80 endogenously present in a microorganism of the genus Corynebacterium or Corynebacterium stationensis, but is not limited thereto.
[0184] Additionally, the base sequence encoding the serine hydroxymethyltransferase may be a base sequence encoding a protein exhibiting the activity of serine hydroxymethyltransferase.
[0185] For example, the serine hydroxymethyltransferase protein having the amino acid sequence of SEQ ID NO: 80 may be encoded by a polynucleotide having or including a sequence of SEQ ID NO: 81 or a base sequence having at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with the sequence of SEQ ID NO: 81, or consisting of or consisting essentially of the base sequence, but is not limited thereto. In addition, the base sequence of SEQ ID NO: 81 can be obtained from a known database, such as, but not limited to, NCBI's GenBank.
[0186]
[0187] As an example of the present application, the microorganism having purine nucleotide production ability of the present application may be a microorganism having enhanced purine nucleotide production ability by further enhancing formate-dependent phosphoribosylglycinamide formyl transferase protein activity compared to the intrinsic activity, but is not limited thereto.
[0188] In the present application, the term “formate-dependent phosphoribosylglycinamide formyltransferase” has an activity that catalyzes the chemical reaction 10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide ⇔ tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide. The formate-dependent phosphoribosylglycinamide formyltransferase of the present application may be used interchangeably as PurT. Specifically, the formate-dependent phosphoribosylglycinamide formyl transferase of the present application may be a protein having formate-dependent phosphoribosylglycinamide formyl transferase activity encoded by the purT gene, but is not particularly limited in type as long as it has an activity corresponding to the formate-dependent phosphoribosylglycinamide formyl transferase. The formate-dependent phosphoribosylglycinamide formyl transferase encoded by the purT gene is known in the art, and the amino acid and polynucleotide sequences of the formate-dependent phosphoribosylglycinamide formyl transferase can be obtained from known databases, including, but not limited to, NCBI's GenBank.
[0189] For example, the formate-dependent phosphoribosylglycinamide formyl transferase protein may include the amino acid sequence of SEQ ID NO: 82 or an amino acid sequence having at least 60% homology or identity thereto, but is not limited thereto, as long as it has formate-dependent phosphoribosylglycinamide formyl transferase protein activity. Specifically, the polypeptide having the formate-dependent phosphoribosylglycinamide formyl transferase protein activity may have, include, consist of, or consist essentially of the amino acid sequence of SEQ ID NO: 82 or an amino acid sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity thereto. For example, the formate-dependent phosphoribosylglycinamide formyltransferase protein may refer to a protein endogenously present in a microorganism of the genus Corynebacterium or Corynebacterium stationensis, but is not limited thereto, and specifically, may refer to a formate-dependent phosphoribosylglycinamide formyltransferase protein consisting of an amino acid sequence of SEQ ID NO: 82 endogenously present in a microorganism of the genus Corynebacterium or Corynebacterium stationensis, but is not limited thereto.
[0190] Additionally, the base sequence encoding the formate-dependent phosphoribosylglycinamide formyl transferase may be a base sequence encoding a protein exhibiting the activity of the formate-dependent phosphoribosylglycinamide formyl transferase.
[0191] For example, the formate-dependent phosphoribosylglycinamide formyl transferase protein having the amino acid sequence of SEQ ID NO: 82 may be encoded by a polynucleotide having, including, or consisting essentially of the sequence of SEQ ID NO: 83 or a base sequence having at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with the sequence of SEQ ID NO: 83, but is not limited thereto. In addition, the base sequence of SEQ ID NO: 83 can be obtained from a known database, such as, but not limited to, NCBI's GenBank.
[0192]
[0193] As a microorganism according to any one of the preceding specific examples, the microorganism having purine nucleotide production ability of the present application may be a microorganism having improved purine nucleotide production ability by having serine dehydratase protein activity weakened compared to the intrinsic activity and serine hydroxymethyltransferase protein activity strengthened compared to the intrinsic activity, but is not limited thereto.
[0194]
[0195] As a microorganism according to any one of the preceding specific examples, the microorganism having purine nucleotide production ability of the present application may be a microorganism having improved purine nucleotide production ability by having serine dehydratase protein activity weakened compared to the intrinsic activity, serine hydroxymethyltransferase protein activity strengthened compared to the intrinsic activity, and glycine decomposition enzyme protein activity strengthened compared to the intrinsic activity, but is not limited thereto.
[0196]
[0197] As a microorganism according to any one of the preceding specific examples, the microorganism having purine nucleotide production ability of the present application may be a microorganism having improved purine nucleotide production ability, such as a microorganism in which serine dehydratase protein activity is weakened compared to the endogenous activity, serine hydroxymethyltransferase protein activity is strengthened compared to the endogenous activity, glycine catabolism protein activity is strengthened compared to the endogenous activity, formate dehydrogenase protein activity is weakened compared to the endogenous activity, and formate-dependent phosphoribosylglycinamide formyl transferase protein activity is strengthened compared to the endogenous activity, but is not limited thereto.
[0198]
[0199] Another aspect of the present application provides a method for producing purine nucleotides, comprising the step of culturing a microorganism in a medium in which the serine dehydratase protein activity of the present application is weakened compared to the intrinsic activity.
[0200] In this application, the term "cultivation" refers to growing the strain of this application under appropriately controlled environmental conditions. The cultivation process of this application can be performed using any suitable medium and culture conditions known in the art. This cultivation process can be easily adjusted and used by those skilled in the art depending on the selected strain. Specifically, the cultivation may be batch, continuous, and / or fed-batch, but is not limited thereto.
[0201] In this application, the term "medium" refers to a material containing nutrients as its main component necessary for culturing the microorganism of this application, and supplies nutrients and growth factors, including water, which is essential for survival and growth. Specifically, the medium and other culture conditions used for culturing the strain of this application may be any medium used for culturing general microorganisms without particular limitation. However, the microorganism of this application may be cultured under aerobic conditions in a general medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid, and / or vitamin, while controlling temperature, pH, etc. For example, a culture medium for a strain of the genus Corynebacterium can be found in the literature ["Manual of Methods for General Bacteriology" by the American Society for Bacteriology (Washington DC, USA, 1981)].
[0202] In the present application, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc.; organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc. In addition, natural organic nutrients such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sugarcane bagasse, and corn steep liquor may be used, and specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted to reducing sugar) may be used, and other appropriate amounts of carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.
[0203] The nitrogen source may include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; organic nitrogen sources such as amino acids such as glutamic acid, methionine, glutamine, etc.; peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its decomposition product, defatted soybean cake or its decomposition product, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.
[0204] The above-mentioned components may include potassium phosphate monobasic, potassium phosphate dibasic, or their corresponding sodium-containing salts. Inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. In addition, amino acids, vitamins, and / or suitable precursors may be included. These components or precursors may be added to the medium in batch or continuous manner, but are not limited thereto.
[0205] In addition, during the cultivation of the microorganism of the present application, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. may be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during the cultivation, foaming may be suppressed by using an antifoaming agent such as fatty acid polyglycol ester. In addition, to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas may be injected into the medium, or to maintain the anaerobic and microaerobic state, nitrogen, hydrogen, or carbon dioxide gas may be injected without gas injection, but is not limited thereto.
[0206] In the culture of the present application, the culture temperature can be maintained at 27 to 37°C, specifically 30 to 33°C, and the culture can be performed for about 20 to 120 hours, but is not limited thereto.
[0207] In the present application, the term "culture" means a culture solution, concentrated culture solution, dried product of culture solution, culture filtrate, concentrated culture filtrate, or dried product of culture filtrate obtained by culturing a specific microorganism in a culture medium, wherein the culture solution means that it contains a specific microorganism, and the culture filtrate means that it does not substantially contain a specific microorganism (here, substantially means that a specific microorganism separated by filtration or the like is excluded, but does not mean that the filtrate is completely free of microorganisms). The culture is not limited in its formulation, and may be, for example, a liquid, an emulsion, or a solid. Specifically, for the purpose of the present application, the culture may contain a purine nucleotide.
[0208] In this application, the term "fermentation" refers to a process in which microorganisms use their enzymes to decompose organic matter, but not to a putrefaction reaction. While fermentation and putrefaction occur through similar processes, if the resulting decomposition produces useful substances, it is called fermentation. If the resulting decomposition produces foul-smelling or harmful substances, it is called putrefaction.
[0209] In the present application, the method for obtaining a fermented product from the strain is not particularly limited, and can be obtained according to a method commonly used in the relevant technical field or a similar field.
[0210] In the present application, the term "fermentation" includes all kinds of materials including a fermentation product produced from the strain, such as not only the fermented material itself, but also a culture medium of the strain in which the strain and the culture coexist, a fermentation product obtained by filtering the strain from the culture medium, a fermentation product obtained by sterilizing the strain from the culture medium and filtering it, an extract obtained by extracting the fermentation product or a culture medium containing it, a diluted solution obtained by diluting the fermentation product or its extract, a concentrate obtained by drying the fermentation product or its extract, a lysate obtained by capturing and crushing the cells of the strain, etc.
[0211] In the method of the present application, any culture conditions and methods known in the art can be used to cultivate microorganisms. Those skilled in the art can easily adjust and use these culture processes according to the selected strain.
[0212] Purine nucleotides produced by the culture of the present invention may be secreted into the medium or remain within the cells.
[0213]
[0214] In one specific embodiment, the method for producing purine nucleotides of the present application may further include a step of preparing a microorganism of the present application, a step of preparing a medium for culturing the strain, or a combination thereof (in any order), for example, prior to the culturing step.
[0215] The purine nucleotide production method of the present application may further include a step of recovering a target substance, specifically a purine nucleotide, from the cultured microorganism, a culture of the microorganism, a fermented product of the microorganism, or the culture medium. The recovering step may be additionally included after the culturing step.
[0216] The above recovery may be to collect the target purine nucleotide using a suitable method known in the art according to the culture method of the microorganism of the present application, for example, a batch, continuous or fed-batch culture method. For example, various chromatographies such as centrifugation, filtration, treatment with a crystallized protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC or a combination thereof may be used, and the target substance, specifically, the purine nucleotide, may be recovered from the medium or microorganism using a suitable method known in the art.
[0217] Additionally, the purine nucleotide production method of the present application may additionally include a purification step. The purification may be performed using any suitable method known in the art. In one example, when the purine nucleotide production method of the present application includes both a recovery step and a purification step, the recovery step and the purification step may be performed sequentially or discontinuously, regardless of order, or may be performed simultaneously or integrated into a single step, but is not limited thereto.
[0218] In the method of the present application, the weakening of serine dehydratase protein activity and purine nucleotides, etc. are as described in the other embodiments above.
[0219]
[0220] Another aspect of the present application provides a composition for producing purine nucleotides, comprising a microorganism having a serine dehydratase protein activity weakened compared to the intrinsic activity of the present application, a culture of the microorganism, a fermentation product of the microorganism, or a combination of two or more thereof.
[0221] The composition of the present application may further comprise any suitable excipient commonly used in compositions for producing purine nucleotides, and such excipients may be, for example, but are not limited to, preservatives, wetting agents, dispersing agents, suspending agents, buffers, stabilizers, or isotonic agents.
[0222] In one specific example, each component present in the composition of the present application may be included in a microbiologically effective amount, or an amount that can be suitably present in the composition for production.
[0223] In the composition of the present application, the attenuation of serine dehydratase protein activity and purine nucleotides, etc. are as described in the other embodiments above.
[0224]
[0225] Another aspect of the present application provides a use of a microorganism for producing purine nucleotides, wherein the serine dehydratase protein activity of the present application is weakened compared to its intrinsic activity.
[0226] In the purpose of the present application, the weakening of serine dehydratase protein activity and purine nucleotides, etc. are as described in the other embodiments above.
[0227]
[0228] The present application will be described in more detail below through examples. However, the following examples are merely preferred embodiments intended to illustrate the present application and are therefore not intended to limit the scope of the present application. Furthermore, technical details not described herein can be readily understood and implemented by those skilled in the technical field of the present application or similar fields.
[0229]
[0230] Example 1. Production of sdaA-deficient microorganisms and confirmation of XMP production ability.
[0231]
[0232] Example 1-1. Construction of a recombinant vector with sdaA deletion and glyA addition enhancement.
[0233]
[0234] We constructed a strain lacking the endogenous gene sdaA of Corynebacterium stationaris and also constructed a strain with additional copies of the glyA gene at the sdaA gene locus to confirm the effects of sdaA deletion and glyA enhancement in XMP production. The vector for this purpose was constructed as follows using plasmid pDCM2 (Korean Publication No. 10-2020-0136813) for insertion and replacement of genes in the Corynebacterium chromosome.
[0235] PCR was performed using the gDNA (genomic DNA) of wild type Corynebacterium stationensis ATCC6872 as a template, with primer pairs of sequences of SEQ ID NOs: 1 and 2 and primer pairs of sequences of SEQ ID NOs: 3 and 4, respectively. PCR was performed at 94°C for 5 minutes, followed by 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute and 30 seconds, and then 72°C for 5 minutes. The pDCM2 vector was treated with XbaI, and the PCR product obtained above was fusion cloned. Fusion cloning was performed using the In-Fusion® HD cloning kit (Clontech). The resulting plasmid was named pDCM2-del sdaA.
[0236] In addition, PCR and cloning were performed in the same manner using primer pairs of sequences 1 and 5, primer pairs of sequences 6 and 7, and primer pairs of sequences 8 and 4. The resulting plasmid was named pDCM2-del sdaA-Pn-glyA.
[0237] The sequences of the primers used for vector construction are as follows.
[0238]
[0239] Sequence number name sequence 1primer5'- acccggggatcctctagaGTGCCGTTACCTCCCGC-3'2primer5'- TGGAGTGCGTAGCGTGCGAAATGACTCCTTTCTAAA-3'3primer5'- TTTAGAAAGGAGTCATTTCGCACGCTACGCACTCCA-3'4primer5'- AAGCTTGCATGCCTGCAGCGTCACCGCGCGGAGATA-3'5primer5'- GAAATGACTCCTTTCTAAAAAGGGG -3'6primer5'- TTAGAAAGGAGTCATTTCGAACTTGCAGCAAACGTGCTG -3'7primer5'- CCTTGGTGAGGCACTTTGTG -3'8primer5'- CAAAGTGCCTCACCAAGGGCACGCTACGCACTCCATATA -3'
[0240] Example 1-2. Production of strains with sdaA deletion and glyA enhancement
[0241]
[0242] The two vectors produced in Example 1-1 were each transformed into Corynebacterium stationenis CJX1664 strain (KR 10-1950141 B1) by electroporation, and then the strain in which the vector was inserted into the chromosome was selected as the primary candidate on a selection medium containing 25 mg / L kanamycin. Thereafter, among the strains in which homologous recombination occurred, a strain in which the sdaA gene was deleted was selected using the primer pair of SEQ ID NO: 1 and SEQ ID NO: 4, and a strain in which the sdaA gene was deleted and the glyA gene linked to its own promoter was inserted at the corresponding position was selected using the primer pair of SEQ ID NO: 9 and SEQ ID NO: 7.
[0243]
[0244] Sequence number name sequence 9 primer 5'- GTCAACGCGCACTTGGATCT-3'
[0245] Example 1-3. Evaluation of XMP production capacity of sdaA deletion and glyA addition-enhanced strains
[0246]
[0247] The XMP production ability of the strains and parent strains produced in the above Examples 1-2 was evaluated through flask fermentation titer evaluation. First, each strain was inoculated into an 18 mm diameter test tube containing 2 ml of seed medium, and cultured with shaking at 30°C for 24 hours to be used as a seed culture. 0.7 ml of the seed culture was inoculated into a 250 ml corner-baffle flask containing 32 ml of the production medium below (24 ml of main medium + 8 ml of a separate sterilized medium), and cultured at 30°C for 75 hours at 170 rpm. After completion of the culture, the XMP production ability was measured by HPLC.
[0248]
[0249] <Seed medium (pH7.5)>
[0250] Glucose 1%, peptone 1%, meat juice 1%, yeast extract 1%, sodium chloride 0.25%, adenine 100mg / l, guanine 100mg / l (based on 1 liter of distilled water)
[0251]
[0252] <XMP 플라스크 생산배지 (본배지)>
[0253] Glucose 40 g / L, Magnesium sulfate 10 g / L, Calcium chloride 100 mg / L, Iron sulfate 20 mg / L, Manganese sulfate 10 mg / L, Zinc sulfate 10 mg / L, Copper sulfate 0.8 mg / L, Histidine 20 mg / L, Cystine 15 mg / L, Beta-Alanine 15 mg / L, Biotin 100 ug / L, Thiamine 5 mg / L, Adenine 50 mg / L, Guanine 25 mg / L, Niacin 15 mg / L, pH 7.0
[0254]
[0255] <XMP Flask Production Medium (Separate Sterilized Medium)>
[0256] Monopotassium phosphate 18 g / L, Monopotassium phosphate 42 g / L, Urea 7 g / L, Ammonium sulfate 5 g / L (based on 1 liter of distilled water)
[0257]
[0258] The above experiment was repeated three times, and the average value of the analysis results is shown in Table 3 below.
[0259]
[0260] Comparison of XMP production of strains with sdaA deletion and glyA copy addition. Strain number. Type of introduction. XMP (g / L). Concentration increase rate (%). CJX1664Control4.32-CJX1664-del_sdaA4.422.32CJX1664-del_sdaA-Pn-glyA4.647.47
[0261] As shown in Table 3 above, the sdaA deletion strain showed a 2.32% increase in XMP production compared to the control group, and the strain with sdaA deletion and increased glyA copy number showed a 7.47% increase in XMP production compared to the control group. It was confirmed that sdaA deletion is effective in improving XMP production, and that when glyA expression is simultaneously enhanced, XMP production is further enhanced. This confirmed that sdaA deletion and glyA enhancement can be useful for XMP production.
[0262]
[0263] Example 2. Production of gcvPTH-enhanced strains based on sdaA deletion and glyA addition-enhanced strains.
[0264]
[0265] Example 2-1. Construction of a gcvPTH copy-adding recombinant vector and a 5'-xanthrylic acid producing strain
[0266]
[0267] To determine whether strengthening the gcvPTH gene could lead to increased XMP production, a vector was constructed by copy-placing the gcvPTH gene of Corynebacterium stationanis strain in the form of a native promoter. The vector was constructed as follows using plasmid pDCM2 (Korean Publication No. 10-2020-0136813), which is designed for insertion and replacement of genes in the Corynebacterium chromosome.
[0268] The chromosomal genes of the wild type Corynebacterium stationensis strain ATCC6872 were isolated using the G-spin Total DNA extraction mini kit (Cat. No. 17045) from Intron according to the protocol provided in the kit, and the gene fragments (Pn / gcvPTH-A, Pn / gcvPTH -B, Pn / gcvPTH -C, Pn / gcvPTH-D) were obtained through polymerase chain reaction using primer pairs of SEQ ID NO: 10 and SEQ ID NO: 11, primer pairs of SEQ ID NO: 12 and SEQ ID NO: 13, primer pairs of SEQ ID NO: 14 and SEQ ID NO: 15, and primer pairs of SEQ ID NO: 16 and SEQ ID NO: 17, respectively. The PCR conditions were denaturation at 94°C for 5 minutes, followed by 20 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute, followed by polymerization at 72°C for 7 minutes.
[0269] The gene fragment obtained above was digested with the restriction enzyme XbaI (New England Biolabs, Beverly, MA). Using T4 ligase (New England Biolabs, Beverly, MA), the gene fragment was ligated into linear pDCM2 (Korean Publication No. 10-2020-0136813) digested with the XbaI restriction enzyme. The constructed vector was named pDCM2-gcvPTH.
[0270] The sequences of the primers used for vector construction are as follows.
[0271]
[0272] Sequence number name sequence 10primer5'- AATTCGAGCTCGGTACCCAGGCACAGCCGACATTACGG -3'11primer5'- GTAGCACATCTGACGAATGTCCAAGTCTAAGGAAA -3'12primer5'- TTAGACTTGGACATTCGTCAGATGTGCTACTTGCC -3'13primer5'- TGCGCCATTAGCGTGTTACTTCTCGCGGCTATAGA -3'14primer5'- AGCCGCGAGAAGTAACACGCTAATGGCGCATTGAA -3'15primer5'- TGAATTATCCGCGTCTTAGATGCCGTTTTCTGCCG-3'16primer5'- GAAAACGGCATCTAAGACGCGGATAATTCAGCTGT -3'17primer5'- CGACTCTAGAGGATCCCCGATGAAGCGAACACTTAAAT -3'
[0273] To determine whether further strengthening of the gcvPTH gene could lead to increased XMP production, experiments were conducted to strengthen gcvPTH in sdaA deletion and glyA additionally strengthened strains.
[0274] The pDCM2-gcvPTH vector constructed above was transformed into an sdaA deletion and glyA addition-enhanced strain by electroporation, and then the strain was first confirmed by PCR using the primer pair of SEQ ID NO: 18 and SEQ ID NO: 19 in a selection medium containing 25 mg / L of kanamycin, and then finally confirmed by gene sequence analysis.
[0275] The sequences of the primers used for strain production are as follows.
[0276]
[0277] Sequence number name sequence 18 primer 5'- CCAGTACATTGTCATGGGAT -3' 19 primer 5'- GATTGGCATATCGCACCGAG -3'
[0278] Example 3. Evaluation of 5'-xanthrylic acid production capacity of gcvPTH-enhanced strains based on glyA-enhanced and sda-deficient strains.
[0279]
[0280] In order to measure the 5'-xanthrylic acid production ability of the strain and parent strain produced in Example 2, a flask titer evaluation was performed. The strain was inoculated into a 14 ml tube containing 2.5 ml of the following seed medium and cultured with shaking at 170 rpm at 30°C for 24 hours. 2 ml of the seed culture was inoculated into a 250 ml corner-baffle flask containing 29 ml of the following production medium (24 ml of main medium + 5 ml of starch medium) and cultured with shaking at 170 rpm at 30°C for 72 hours. After completion of the culture, the amount of XMP production was measured by a method using HPLC.
[0281]
[0282] The composition of the above-mentioned seed medium and fermentation medium is the same as in Example 1-3.
[0283]
[0284] The culture results according to glyA enhancement, sdaA deletion integration, and gcvPTH enhancement in Corynebacterium stationarus KCCM12151P, an XMP-producing strain, are shown in Table 6 below.
[0285]
[0286] Confirmation of 5'-xanthrylic acid production by integration of glyA enhancement, sdaA deletion, and gcvPTH enhancement. Strain number, introduction type, XMP (g / L), concentration increase rate (%), CJX1664 Control 4.51-CJX1664-del_sdaA-Pn-glyA 4.85 7.45 CJX1664-del_sdaA-Pn-glyA- Pn / gcvPTH 5.48 21.5
[0287] Deletion of sdaA and enhancement of glyA in XMP-producing strains can lead to increased production of 5'-xanthrylic acid, and additionally, when gcvPTH was enhanced together, the concentration of 5'-xanthrylic acid was confirmed to further increase.
[0288]
[0289] Example 4. Production of strains with sdaA deletion and glyA enhancement, gcvPTH enhancement, fdh deletion, and purT enhancement.
[0290]
[0291] Example 4-1. Construction of a recombinant vector with fdh deletion and purT addition and a strain producing 5'-xanthrylic acid.
[0292]
[0293] Formate dehydrogenase from Corynebacterium stationensis can be composed of formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2), and formate dehydrogenase subunit 3 (Fdh subunit 3).
[0294] In order to delete formate dehydrogenase subunit 1, formate dehydrogenase subunit 2, and formate dehydrogenase subunit 3 (hereinafter referred to as formate dehydrogenase), the fdh 1, fdh 2, and fdh 3 genes (hereinafter referred to as fdh genes), which are endogenous genes of Corynebacterium stationani encoding formate dehydrogenase subunit 1 (Fdh subunit 1), formate dehydrogenase subunit 2 (Fdh subunit 2), and formate dehydrogenase subunit 3 (Fdh subunit 3), respectively, were deleted, and a vector was constructed in the form of adding a copy number of the purT gene to the corresponding gene position, and ultimately, the synergistic effect with gcvPTH enhancement in the XMP producing strain was confirmed. Therefore, an experiment was conducted in which fdh was deleted and a copy number of purT was added to the corresponding gene position.
[0295] The chromosomal genes of Corynebacterium stationensis wild type ATCC6872 strain were isolated using the G-spin Total DNA extraction mini kit (Cat. No. 17045) from Intron according to the protocol provided in the kit, and the gene fragments (del_fdh::Pcj7 / purT-A, del_fdh::Pcj7 / purT-B, del_fdh::Pcj7 / purT-C, del_fdh::Pcj7 / purT-D) were obtained through polymerase chain reaction using primer pairs of SEQ ID NO: 20 and SEQ ID NO: 21, primer pairs of SEQ ID NO: 22 and SEQ ID NO: 23, primer pairs of SEQ ID NO: 24 and SEQ ID NO: 25, and primer pairs of SEQ ID NO: 26 and SEQ ID NO: 27, respectively. The PCR conditions were denaturation at 94°C for 5 minutes, followed by 20 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute and 30 seconds, followed by polymerization at 72°C for 7 minutes.
[0296] The gene fragments obtained by performing the second PCR using the four fragments obtained above as templates were digested with the restriction enzyme XbaI (New England Biolabs, Beverly, MA). Using T4 ligase (New England Biolabs, Beverly, MA), the gene fragments were ligated to linear pDCM2 (Korean Publication No. 10-2020-0136813) digested with the XbaI restriction enzyme. The resulting plasmid was named pDCM2-del_fdh-Pcj7 / purT.
[0297] The sequences of the primers used for vector construction are as follows.
[0298]
[0299] Sequence number name sequence 20primer5'- TCGAGCTCGGTACCCGTTGCCGTATCAGACATGCTCAG -3'21primer5'- GATTAGCCTGAAGGAATTGATTTATCTCGACCAAACAG -3'22primer5'- GGTCGAGATAAATCAATTCCTTCAGGCTAATCTTTTCC -3'23primer5'- CGATATAAGACTCCATCATATGTGTTTCCTTTCGTTGG-3'24primer5'- AAAGGAAACACATATGATGGAGTCTTATATCGGTAGCC -3'25primer5'- CTCATAGGTGCCGAACTTACTCGGAGATTTCGACCTCA-3'26primer5'- CGAAATCTCCGAGTAAGTTCGGCACCTATGAGAATATG -3'27primer5'- CTCTAGAGGATCCCCGGCAAGTGTTTCTTGGCGCCATTC-3'
[0300] The above pDCM2-del_fdh-Pcj7 / purT vector was transformed into the strain (CJX1664-del_sdaA-Pn-glyA- Pn / gcvPTH) constructed in Example 2 by electroporation, and then a strain in which the mutant gene and the vector were inserted together on the chromosome was selected as a primary candidate in a selection medium containing 25 mg / L of kanamycin. Thereafter, in the strain in which homologous recombination occurred, a strain in which the fdh gene was deleted and the purT gene linked to the Pcj7 promoter was inserted at the corresponding position was selected using the primer pair of SEQ ID NO: 28 and SEQ ID NO: 29.
[0301] The sequences of the primers used for strain production are as follows.
[0302]
[0303] Sequence number name sequence 28 primer 5'- TAATCCCCCAGCTCACCGGC-3' 29 primer 5'- TTTGGATGCCGAGGTCGTAG-3'
[0304] Example 5. Evaluation of 5'-xanthrylic acid production ability of sdaA deletion and glyA enhancement-based, gcvPTH enhancement, purT enhancement, and fdh deletion integrated strains.
[0305]
[0306] In order to measure the XMP production ability of the strains and parent strains produced in Examples 2 and 4, a flask titer evaluation was performed. Each strain was inoculated into a 14 ml tube containing 2.5 ml of the following seed medium and cultured with shaking at 170 rpm at 30°C for 24 hours. 2 ml of the seed culture was inoculated into a 250 ml corner-baffle flask containing 29 ml of the following production medium (24 ml of main medium + 5 ml of starch medium) and cultured with shaking at 170 rpm at 30°C for 72 hours. After completion of the culture, the XMP production amount was measured by a method using HPLC.
[0307]
[0308] The composition of the above-mentioned seed medium and fermentation medium is the same as in Example 1-3.
[0309]
[0310] The culture results based on the sdaA deletion and glyA enhancement strains in the XMP producing strain, and the integration of gcvPTH enhancement, purT enhancement, and fdh deletion are shown in Table 9 below.
[0311]
[0312] Confirmation of 5'-xanthrylic acid production according to gcvPTH enhancement, sdaA deletion, glyA enhancement, purT enhancement, and fdh deletion integration. Strain number, introduction type, XMP (g / L), concentration increase rate (%), CJX1664Control, 4.48-CJX1664-del_sdaA-Pn-glyA, 4.8, 17.39, CJX1664-del_sdaA-Pn-glyA- Pn / gcvPTH, 5.47, 22.2, CJX1664-del_sdaA-Pn-glyA- Pn / gcvPTH, 2.59, 24.8
[0313] When sdaA deletion, glyA enhancement, and gcvPTH enhancement were combined in an XMP-producing strain, it could lead to an increase in XMP production. In addition, when fdh was deleted and purT was enhanced at the corresponding position by increasing the copy number, it was confirmed that the XMP concentration further increased.
[0314]
[0315] Example 6. Confirmation of GMP production ability of integrated strains based on sdaA deletion and glyA enhancement, gcvPTH enhancement, purT enhancement, and fdh deletion.
[0316]
[0317] In order to confirm GMP production using the XMP culture solution of the strains produced in Examples 1, 2, and 4 and the control parent strain, the XMP production ability was first analyzed through a flask fermentation titer evaluation using the following method. (Refer to Korean Patent Publication No. 10-2011-0105662 A).
[0318] Specifically, the strain was cultured using the fermentation activity evaluation method of Example 1-3 above. After completion of the culture, the production amount of XMP (5'-xanthyl acid) was measured using a method using HPLC.
[0319] Next, the GMP production capacity was analyzed. Specifically, in order to convert the produced XMP into GMP, the following conversion reaction additives and E. coli XMP aminase were added to the flask fermentation liquid, and the conversion reaction was performed at 40°C for 2.5 hours. As a result of the above experiment, the conversion rate results, which indicate the amount of GMP produced relative to the amount of XMP consumed, are shown in Table 10 below.
[0320]
[0321] Confirmation of GMP production ability of strains with sdaA deletion and glyA copy addition Strain number Introduction type XMP (g / L) GMP (g / L) Conversion rate (%) (GMP production amount / XMP consumption amount) CJX1664Control 4.433.2 372.9 CJX1664-del_sdaA 4.533.3173.0 CJX1664-del_sdaA-Pn-glyA 4.763.4873.1 CJX1664-del_sdaA-Pn-glyA- Pn / gcvPTH 5.423.9673.0 CJX1664-del_sdaA-Pn-glyA- Pn / gcvPTH-del_fdh-Pcj7 / purT 5.544.0 673.2
[0322] As shown in Table 10 above, it was confirmed that GMP was produced through a conversion reaction from XMP produced by the strain.
[0323]
[0324] <Conversion reaction additive>
[0325] Phytic acid 1.8g / L, magnesium sulfate 4.8g / L, nymeen 3㎖ / L, xylene 2%, adenine 100mg / L, sodium hydrogen phosphate (Na2HPO4) 7.7g / L, glutamine 2g / L, glucose 46g / L
[0326]
[0327] Example 7. Production of sdaA-deficient microorganisms and confirmation of IMP production capacity.
[0328]
[0329] Example 7-1. Construction of sdaA gene deletion vector
[0330]
[0331] To delete the endogenous gene sdaA of Corynebacterium stationensis, plasmid pDCM2 (Korean Publication No. 10-2020-0136813) was used to construct as follows.
[0332] PCR was performed using the gDNA (genomic DNA) of wild type Corynebacterium stationensis ATCC6872 as a template, with primer pairs of sequences SEQ ID NOs: 30 and 31 and primer pairs of sequences SEQ ID NOs: 32 and 33, respectively. PCR was performed at 94°C for 5 minutes, followed by 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute, and then 72°C for 5 minutes. The pDCM2 vector was treated with XbaI, and the PCR product obtained above was fusion cloned. Fusion cloning was performed using the In-Fusion® HD cloning kit (Clontech). The resulting plasmid was named pDCM2-del sdaA(I).
[0333] The sequences of the primers used for vector construction are as follows.
[0334]
[0335] Sequence number name sequence 30primer5'- AATTCGAGCTCGGTACCCCATTTCGTGACCATTAGCGT-3'31primer5'- CTTTGTACTTGGTGAGATCATGCCAATAGCGCCAG-3'32primer5'- GCTATTGGCATGATCTCACCAAGTACAAAGAGACT-3'33primer5'- CGACTCTAGAGGATCCCCGGTTACCGCGCATTAGGACT-3'
[0336] Example 7-2. Production of sdaA gene-deficient strain
[0337]
[0338] The vector constructed in Example 7-1 was transformed into Corynebacterium stationensis KCCM12151P by electroporation, and a strain in which the vector was inserted into the chromosome was selected as a primary candidate on a selection medium containing 25 mg / L kanamycin. Thereafter, a strain with a deletion of the sdaA gene was selected from the strains in which homologous recombination occurred using the primer pair of SEQ ID NO: 34 and SEQ ID NO: 35. The strain with a deletion of serine dehydratase obtained in the above manner was named CJI-3176 (KCCM12151P_sda_deletion).
[0339]
[0340] Sequence number name sequence 34 primer 5'- TAATCCCCCAGCTCACCGGC -3' 35 primer 5'- TTTGGATGCCGAGGTCGTAG -3'
[0341] Example 7-3. Evaluation of IMP production capacity of sdaA gene-deficient strain
[0342]
[0343] The IMP production ability of the strains and parent strains produced in Example 7-2 above was evaluated through flask fermentation titer evaluation. Corynebacterium stationensis KCCM12151P, CJI-3176 were inoculated into a 14 ml tube containing 2.5 ml of the following seed medium and cultured with shaking at 170 rpm at 30°C for 24 hours. 2 ml of the seed culture was inoculated into a 250 ml corner-baffle flask containing 29 ml of the following production medium (24 ml of main medium + 5 ml of starch medium) and cultured with shaking at 170 rpm at 30°C for 72 hours. After completion of the culture, the production amount of 5'-inosinic acid was measured by a method using HPLC.
[0344]
[0345] The composition of the above-mentioned seed medium and fermentation medium is as follows.
[0346]
[0347] <IMP종배지>
[0348] Glucose 1%, peptone 1%, meat juice 1%, yeast extract 1%, sodium chloride 0.25%, adenine 100 mg / L, guanine 100 mg / L, pH 7.2
[0349]
[0350] <IMP 플라스크 발효배지>
[0351] Added sodium glutamate 0.1%, ammonium chloride 1%, magnesium sulfate 1.2%, calcium chloride 0.01%, iron sulfate 20 mg / L, manganese sulfate 20 mg / L, zinc sulfate 20 mg / L, copper sulfate 5 mg / L, L-cysteine 23 mg / L, beta-alanine 24 mg / L, nicotinic acid 8 mg / L, biotin 45 μg / L, thiamine hydrochloride 5 mg / L, adenine 30 mg / L, phosphoric acid (85%) 1.9%, glucose 4.2%, and fructose 2.4%
[0352]
[0353] The culture results of Corynebacterium stationaris with a deficiency of serine dehydratase are shown in Table 13 below.
[0354]
[0355] Confirmation of 5'-inosinic acid production according to serine dehydratase deficiency. Strain number. Introduction type. OD. 5'-inosinic acid (g / L). Concentration increase rate (%). KCCM12151P. Control 41.35.2-CJI-3176 △sda 40.85.55.7
[0356] We confirmed that an increase in the serine pool due to a deficiency of serine dehydratase within the IMP-producing strain can lead to an increase in 5'-inosinic acid production.
[0357]
[0358] Example 8. Production of strains lacking sdaA and enhanced with glyA and evaluation of IMP production capacity.
[0359]
[0360] Example 8-1. Construction of a recombinant vector with sdaA deletion and glyA addition enhancement and a strain producing 5'-inosinic acid.
[0361]
[0362] We aimed to confirm the synergistic effect by deleting the sdaA gene, an endogenous gene of Corynebacterium stationaris, and adding copies of the glyA gene to the corresponding gene locus. Therefore, an experiment was conducted in which sdaA was deleted from CJI-3176 manufactured in Example 7-2, and copies of glyA were added to the corresponding gene locus.
[0363] The chromosomal genes of the wild type Corynebacterium stationensis strain ATCC6872 were isolated using the G-spin Total DNA extraction mini kit (Cat. No. 17045) from Intron according to the protocol provided in the kit, and the gene fragments (del_sda::Pcj7 / glyA-A, del_sda::Pcj7 / glyA -B, del_sda::Pcj7 / glyA -C, del_sda::Pcj7 / glyA -D) were obtained through polymerase chain reaction using primer pairs of SEQ ID NO: 36 and SEQ ID NO: 37, primer pairs of SEQ ID NO: 38 and SEQ ID NO: 39, primer pairs of SEQ ID NO: 40 and SEQ ID NO: 41, and primer pairs of SEQ ID NO: 42 and SEQ ID NO: 43, respectively. The PCR conditions were denaturation at 94°C for 5 minutes, followed by 20 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute, followed by polymerization at 72°C for 7 minutes.
[0364] The gene fragments obtained by performing the second PCR using the four fragments obtained above as templates were digested with the restriction enzyme XbaI (New England Biolabs, Beverly, MA). Using T4 ligase (New England Biolabs, Beverly, MA), the gene fragments were ligated to linear pDCM2 (Korean Publication No. 10-2020-0136813) digested with the XbaI restriction enzyme. The resulting plasmid was named pDCM2-del_sdaA-Pn / glyA.
[0365] The sequences of the primers used for vector construction are as follows.
[0366]
[0367] SEQ ID NO: NAME Sequence 36primer5'- AATTCGAGCTCGGTACCCCATTTCGTGACCATTAGCGT -3'37primer5'- ATTAGCCTGAAGGAAGATCATGCCAATAGCGCCAG -3'38primer5'- GCTATTGGCATGATCTTCCTTCAGGCTAATCTTTT -3'39primer5'-ATTCTGGGTAGTCATCATATGTGTTTCCTTTCGTT-3'40primer5'- AAGGAAACACATATGATGACTACCCAGAATTCTTC -3'41primer5'- CTTTGTACTTGGTGACCAAGAGTCAGGATGCCGAA-3'42primer5'- CATCCTGACTCTTGGTCACCAAGTACAAAGAGACT -3'43primer5'- CGACTCTAGAGGATCCCCGGTTACCGCGCATTAGGACT-3'
[0368] The pDCM2-del_sdaA-Pcj7 / glyA vector was transformed into the CJI-3176 strain constructed in Example 7-2 by electroporation, and a strain in which the mutant gene and the vector were inserted together on the chromosome was selected as a primary candidate in a selection medium containing 25 mg / L of kanamycin. Thereafter, in the strain in which homologous recombination occurred, a strain in which the sdaA gene was deleted and the glyA gene linked to the Pcj7 promoter was inserted at the corresponding position was selected using the primer pair of SEQ ID NO: 44 and SEQ ID NO: 45. The strain obtained in the above manner was named CJI-3177 (CJI-3176_del_sdaA-Pn / glyA).
[0369] The sequences of the primers used for strain production are as follows.
[0370]
[0371] Sequence number name sequence 44 primer 5'- TAATCCCCCAGCTCACCGGC-3' 45 primer 5'- TTTGGATGCCGAGGTCGTAG-3'
[0372] Example 8-2. Evaluation of IMP production ability of strains produced by sdaA deletion and glyA addition enhancement
[0373]
[0374] The IMP production ability of the strains and parent strains produced in the above Examples 7-2 and 8-1 was evaluated through flask fermentation titer evaluation. Corynebacterium stationensis KCCM12151P, CJI-3176, and CJI-3177 were inoculated into a 14 ml tube containing 2.5 ml of the following seed medium and cultured with shaking at 170 rpm at 30°C for 24 hours. 2 ml of the seed culture was inoculated into a 250 ml corner-baffle flask containing 29 ml of the following production medium (24 ml of main medium + 5 ml of star medium) and cultured with shaking at 170 rpm at 30°C for 72 hours. After the culture was completed, the production amount of 5'-inosinic acid was measured by a method using HPLC.
[0375]
[0376] The composition of the above-mentioned seed medium and fermentation medium is as follows.
[0377]
[0378] <IMP종배지>
[0379] Glucose 1%, peptone 1%, meat juice 1%, yeast extract 1%, sodium chloride 0.25%, adenine 100 mg / L, guanine 100 mg / L, pH 7.2
[0380]
[0381] <IMP 플라스크 발효배지>
[0382] Added sodium glutamate 0.1%, ammonium chloride 1%, magnesium sulfate 1.2%, calcium chloride 0.01%, iron sulfate 20 mg / L, manganese sulfate 20 mg / L, zinc sulfate 20 mg / L, copper sulfate 5 mg / L, L-cysteine 23 mg / L, beta-alanine 24 mg / L, nicotinic acid 8 mg / L, biotin 45 μg / L, thiamine hydrochloride 5 mg / L, adenine 30 mg / L, phosphoric acid (85%) 1.9%, glucose 4.2%, and fructose 2.4%
[0383]
[0384] The culture results of Corynebacterium stationaris with a deficiency of serine dehydratase are shown in Table 16 below.
[0385]
[0386] Confirmation of 5'-inosinic acid production according to serine dehydratase deficiency Strain number Introduction type OD 5'-inosinic acid (g / L) Concentration increase rate (%) KCCM12151 P Control 4 1.35.2-CJI-3176 △sda 4 0.8 5.5 5.7 CJI-3177 CJI-3176 -del_sdaA- Pcj7 / glyA 3 9.25.9 13.4
[0387] We confirmed that the enhancement of serine pool due to the deficiency of serine dehydratase within the IMP-producing strain and the additional copy enhancement of glyA had a synergistic effect on increasing 5'-inosinic acid production.
[0388]
[0389] Example 9. Production and evaluation of gcvPTH-enhanced, fdh-deficient, and purT-enhanced strains based on sdaA deletion and glyA additional enhancement strains (IMP)
[0390]
[0391] Example 9-1. Construction of gcvPTH additionally enhanced recombinant vector and 5'-inosinic acid strain
[0392]
[0393] A vector was constructed to copy the endogenous gcvPTH gene of Corynebacterium stationensis strain in the form of a native promoter. The vector was constructed as follows using plasmid pDCM2 (Korean Publication No. 10-2020-0136813), which is designed for gene insertion and replacement within the Corynebacterium chromosome.
[0394] The chromosomal gene of Corynebacterium stationensis wild type ATCC6872 strain was isolated using the G-spin Total DNA extraction mini kit (Cat. No. 17045) from Intron according to the protocol provided in the kit, and the gene fragments (Pn / gcvPTH-A, Pn / gcvPTH -B, Pn / gcvPTH -C, Pn / gcvPTH-D) were obtained through polymerase chain reaction using primer pairs of SEQ ID NO: 46 and SEQ ID NO: 47, primer pairs of SEQ ID NO: 48 and SEQ ID NO: 49, primer pairs of SEQ ID NO: 50 and SEQ ID NO: 51, and primer pairs of SEQ ID NO: 52 and SEQ ID NO: 53, respectively. The PCR conditions were denaturation at 94°C for 5 minutes, followed by 20 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute, followed by polymerization at 72°C for 7 minutes.
[0395] The gene fragment obtained above was digested with the restriction enzyme XbaI (New England Biolabs, Beverly, MA). Using T4 ligase (New England Biolabs, Beverly, MA), the gene fragment was ligated into linear pDCM2 (Korean Publication No. 10-2020-0136813) digested with the XbaI restriction enzyme. The constructed vector was named pDCM2-Pn / gcvPTH.
[0396] The sequences of the primers used for vector construction are as follows.
[0397]
[0398] SEQ ID NO: Name Sequence 46Pn / gcvPTH-A-F5'- AATTCGAGCTCGGTACCCAGGCACAGCCGACATTACGG -3'47Pn / gcvPTH-A-R5'- GTAGCACATCTGACGAATGTCCAAGTCTAAGGAAA -3'48Pn / gcvPTH-B-F5'- TTAGACTTGGACATTCGTCAGATGTGCTACTTGCC -3'49Pn / gcvPTH-B-R5'- TGCGCCATTAGCGTGTTACTTCTCGCGGCTATAGA -3'50Pn / gcvPTH-C-F5'- AGCCGCGAGAAGTAACACGCTAATGGCGCATTGAA -3'51Pn / gcvPTH-C-R5'- TGAATTATCCGCGTCTTAGATGCCGTTTTCTGCCG-3'52Pn / gcvPTH-D-F5'- GAAAACGGCATCTAAGACGCGGATAATTCAGCTGT -3'53Pn / gcvPTH-D-R5'- CGACTCTAGAGGATCCCCGATGAAGCGAACACTTAAAT -3'
[0399] Example 9-2. Production of a 5'-inosinic acid producing strain with an enhanced gcvPTH gene.
[0400]
[0401] An experiment was conducted to enhance gcvPTH in the CJI-3177 (CJI-3176_del_sdaA-Pn / glyA) strain produced in the above Example 8-1. The pDCM2-Pn / gcvPTH vector produced in the above Example 9-1 was transformed into the CJI-3177 (CJI-3176_del_sdaA-Pn / glyA) strain produced in the above Example 8-1 by electroporation, and then a strain in which the mutant gene and the vector were inserted together on the chromosome was selected as a primary candidate in a selection medium containing 25 mg / L of kanamycin. Afterwards, in the strain in which homologous recombination occurred, the primary confirmation was performed through PCR using the primer pair of SEQ ID NO: 54 and SEQ ID NO: 55, and the final confirmation was performed through gene sequence analysis. The selected strains were named CJI-3192 (CJI-3177_Pn / gcvPTH).
[0402]
[0403] Sequence number name sequence 54 primer 5'- CCAGTACATTGTCATGGGAT-3' 55 primer 5'- GATTGGCATATCGCACCGAG -3'
[0404] Example 9-3. Construction of a recombinant vector with fdh deletion and purT addition enhancement and a 5'-inosinic acid producing strain.
[0405]
[0406] A vector was constructed by deleting the fdh gene, an endogenous gene of Corynebacterium stationaris, and adding copies of the purT gene to the corresponding gene locus. This was done to ultimately confirm the synergistic effect with gcvPTH enhancement in the IMP producing strain. Therefore, an experiment was conducted in which fdh was deleted from CJI-3192, constructed in Example 9-2, and copies of purT were added to the corresponding gene locus.
[0407] The chromosomal genes of the wild type Corynebacterium stationensis strain ATCC6872 were isolated using the G-spin Total DNA extraction mini kit (Cat. No. 17045) from Intron according to the protocol provided in the kit, and the gene fragments (del_fdh::Pcj7 / purT-A, del_fdh::Pcj7 / purT-B, del_fdh::Pcj7 / purT-C, del_fdh::Pcj7 / purT-D) were obtained through polymerase chain reaction using primer pairs of SEQ ID NO: 56 and SEQ ID NO: 57, primer pairs of SEQ ID NO: 58 and SEQ ID NO: 59, primer pairs of SEQ ID NO: 60 and SEQ ID NO: 61, and primer pairs of SEQ ID NO: 62 and SEQ ID NO: 63, respectively. The PCR conditions were denaturation at 94°C for 5 minutes, followed by 20 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute and 30 seconds, followed by polymerization at 72°C for 7 minutes.
[0408] The gene fragments obtained by performing the second PCR using the four fragments obtained above as templates were digested with the restriction enzyme XbaI (New England Biolabs, Beverly, MA). Using T4 ligase (New England Biolabs, Beverly, MA), the gene fragments were ligated to linear pDCM2 (Korean Publication No. 10-2020-0136813) digested with the XbaI restriction enzyme. The resulting plasmid was named pDCM2-del_fdh-Pcj7 / purT.
[0409] The sequences of the primers used for vector construction are as follows.
[0410]
[0411] Sequence number name sequence 56primer5'- TCGAGCTCGGTACCCGTTGCCGTATCAGACATGCTCAG -3'57primer5'- GATTAGCCTGAAGGAATTGATTTATCTCGACCAAACAG -3'58primer5'- GGTCGAGATAAATCAATTCCTTCAGGCTAATCTTTTCC -3'59primer5'- CGATATAAGACTCCATCATATGTGTTTCCTTTCGTTGG-3'60primer5'- AAAGGAAACACATATGATGGAGTCTTATATCGGTAGCC -3'61primer5'- CTCATAGGTGCCGAACTTACTCGGAGATTTCGACCTCA-3'62primer5'- CGAAATCTCCGAGTAAGTTCGGCACCTATGAGAATATG -3'63primer5'- CTCTAGAGGATCCCCGGCAAGTGTTTCTTGGCGCCATTC-3'
[0412] The pDCM2-del_fdh-Pcj7 / purT vector was transformed into the CJI-3192 strain (IMP producing strain) constructed in Example 9-2 by electroporation, and a strain in which the mutant gene and the vector were inserted together on the chromosome was selected as a primary candidate in a selection medium containing 25 mg / L of kanamycin. Thereafter, in the strain in which homologous recombination occurred, a strain in which the fdh gene was deleted and the purT gene linked to the Pcj7 promoter was inserted at the corresponding position was selected using the primer pair of SEQ ID NO: 64 and SEQ ID NO: 65. The strain obtained by the above method was named CJI-3193 (CJI-3192-del_fdh-Pcj7 / purT).
[0413] The sequences of the primers used for strain production are as follows.
[0414]
[0415] Sequence number name sequence 64 primer 5'-GCGAGGGGGAAGAAAAGTA -3' 65 primer 5'- CGTTGCCCTTTTTCTTCT -3'
[0416] Example 10. Confirmation of 5'-inosinic acid production ability of gcvPTH-enhanced, fdh-deficient, and purT-enhanced strains based on glyA-enhanced and sda-deficient strains.
[0417]
[0418] In order to measure the 5'-inosinic acid production ability of the strains and parent strains produced in Examples 9-2 and 9-3, a flask titer evaluation was performed. Corynebacterium stationensis KCCM12151P, CJI-3192, and CJI-3193 were inoculated into a 14 ml tube containing 2.5 ml of the following seed medium, and the mixture was shaken and cultured at 30°C for 24 hours at 170 rpm. 2 ml of the seed culture was inoculated into a 250 ml corner-baffle flask containing 29 ml of the following production medium (24 ml of main medium + 5 ml of starch medium), and the mixture was shaken and cultured at 30°C for 72 hours at 170 rpm. After completion of the culture, the production amount of 5'-inosinic acid was measured by a method using HPLC.
[0419]
[0420] The composition of the above-mentioned seed medium and fermentation medium is the same as in Example 8-2.
[0421]
[0422] The culture results according to the combination of formate dehydrogenase deficiency and formate-dependent phosphoribosylglycinamide formyltransferase enhancement and gcvPTH enhancement, glyA enhancement, and sda deficiency of Corynebacterium stationensis are shown in Table 21 below.
[0423]
[0424] 5'-Inosinic acid production confirmed by combination of formate dehydrogenase deficiency and formate-dependent phosphoribosylglycinamide formyltransferase enhancement and gcvPTH enhancement, glyA enhancement, and sda deletion. Strain number, introduction type, OD, 5'-Inosinic acid (g / L), concentration increase rate (%), KCCM12151, PControl40.15.3-CJI-3192, CJI-3177_Pn / gcvPTH39.16.2, 16.9, CJI-3193, CJI-3192_del_fdh-Pcj7 / PurT39.46.9, 30.1
[0425] When sdaA deletion, glyA enhancement, and gcvPTH enhancement were combined in an IMP-producing strain, it could lead to an increase in IMP production. In addition, when fdh was deleted and purT was enhanced at the corresponding position by increasing the copy number, it was confirmed that the IMP concentration further increased.
[0426]
[0427] From the above description, those skilled in the art will understand that the present application can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of this application should be interpreted to include all changes or modifications derived from the meaning and scope of the following claims and their equivalents, rather than the detailed description above.
Claims
1. A microorganism having purine nucleotide production ability and having a weakened serine dehydratase protein activity compared to the intrinsic activity.
2. A microorganism having purine nucleotide production ability, wherein the serine dehydratase in paragraph 1 is composed of an amino acid sequence of sequence number 66.
3. In paragraph 1, the microorganism is a microorganism having purine nucleotide production ability, wherein the activity of at least one protein selected from the group consisting of (a) to (d) is further regulated: (a) Formate dehydrogenase protein activity is weakened compared to intrinsic activity; (b) Glycine catabolism enzyme protein activity is enhanced compared to the intrinsic activity; (c) enhanced serine hydroxymethyltransferase protein activity compared to intrinsic activity; and (d) Enhanced formate-dependent phosphoribosylglycinamide formyl transferase protein activity compared to intrinsic activity.
4. A microorganism having purine nucleotide production ability, wherein the microorganism in paragraph 1 is a microorganism of the genus Corynebacterium.
5. A microorganism having purine nucleotide production ability, wherein the microorganism of the genus Corynebacterium in paragraph 4 is Corynebacterium stationaris.
6. A microorganism having purine nucleotide production ability, wherein the microorganism has increased purine nucleotide production ability compared to a non-modified microorganism according to any one of claims 1 to 5.
7. A method for producing purine nucleotides, comprising a step of culturing a microorganism in a medium in which serine dehydratase protein activity is weakened compared to the intrinsic activity.
8. A method according to claim 7, further comprising a step of recovering a target substance from the cultured microorganism, a culture of the microorganism, a fermented product of the microorganism, or the culture medium.
9. A composition for producing purine nucleotides, comprising a microorganism having a weakened serine dehydratase protein activity compared to the intrinsic activity, a culture of the microorganism, a fermented product of the microorganism, or a combination of two or more thereof.
10. Purine nucleotide production use of microorganisms with weakened serine dehydratase protein activity compared to their intrinsic activity.
